

42

BioTOPics

Journal of Biotechnology in Berlin-Brandenburg

Issue 42 · June 2011

BioTOP-Report 2011





You need commitment, focus and passion to find new ways to fight the diseases of this world: innovation is at the heart of it.

Innovation for better health. Our commitment is to bring to patients around the world quality medicines for use in diagnosing, combating and preventing disease. Every day we work against time, researching new pathways, new molecules, new technologies – complementing our own capabilities with expertise of innovative partners from science and industry.

The success of this work is evidenced in new medicines for areas with significant unmet medical need such as oncology, cardiovascular and blood diseases, as well as gynecology and molecular imaging. Our aim is a better quality of life for all.

Bayer – Science For A Better Life.

www.bayerhealthcarepharmaceuticals.com
www.bayerhealthcare.com



Bayer HealthCare

Content

The BioCapital Region	5
A Reputation for Excellence in Life Sciences	6
Exploring the Regenerative Potential of the Human Body	12
In Vitro-Diagnostics for the World Market	16
Excellence in Drug Discovery and Development	22
Technologies for the Bio-Based Economy	26
Returning to Growth	28
Surprising Turnaround in VC Financing	36
The BioCampus Network Berlin-Brandenburg	38
From Basics to Very Special Things	42
Excellent Corporate Locating and Project Development Services	44
Addresses	47

Publisher: BioTOP Berlin-Brandenburg
 Fasanenstraße 85 · D-10623 Berlin
 Phone +49 30 318622-0
 Fax +49 30 318622-22
 biotop@biotop.de · www.biotop.de

Editor: Thilo Spahl

Design & Production: supiran.de

Translation: Textbüro Reul GmbH · Frankfurt

Photos: p. 4: Stephanie Eißrig
 p. 8: World Health Summit
 p. 13: Helmholtz-Zentrum Geesthacht
 p. 17: Christoph Heidrich
 p. 26: Leibniz-Institut für Agrartechnik
 Potsdam-Bornim e. V.
 p. 30: Peitz, Charité – Universitätsmedizin Berlin
 p. 42 (left): Rustam Shanov | Dreamstime.com
 p. 43: Heike Zappe
 p. 44: Berlin Partner GmbH
 Others: Authors or BioTOP

BioTOP is a joint initiative of the state of Berlin and the state of Brandenburg under the umbrella of the TSB Innovationsagentur Berlin GmbH and part of the cluster management Health Capital. BioTOP is funded by the federal state of Berlin, the federal state of Brandenburg and the Investitionsbank Berlin, cofunded by the European Union (European Fund for Regional Development).



Deutsche Biotechnologietage 2010

.....

In April 2010 the first "German Biotechnology Days" took place in Berlin. The important national event for the biotechnology industry attracted more than 600 participants, who discussed the major trends affecting the industry.



The BioCapital Region

Germany's capital region is among Europe's leading hubs for biotechnology and pharma. This success is based on the excellence of the research institutes in our region, the innovative power of the companies located here, and the close links between science and industry that have evolved. No less than five universities, four universities of applied sciences, 19 major research institutes, 200 biotech- and 23 pharma companies are engaged in research and development of new high-tech products.



10 years ago, in February 2001, BioTOP published the first of its yearly reports on the life sciences sector in Berlin and Brandenburg. In this first report we described technology fields that seemed most promising to us, and we predicted rapid growth in

employment in the years to come. Today we are happy to state that Berlin-Brandenburg is very well positioned in many of the fields we had identified as strengths that were to be developed. For glycobiochemistry the region has become the place to be. It is home of world renowned researchers, for instance at the Max Planck Institute of Colloids and Interfaces, and leading companies like Glycotope. Tissue Engineering has become an important constituent of regenerative medicine, and with the Berlin Brandenburg Center for Regenerative Therapies the region has earned worldwide reputation in this dynamic field. Biohybrid technologies that were originally developed at the University of Potsdam are today a basis of our rapidly developing diagnostic industry. So biotechnology has really become one of the big assets of the region. We must however admit that – like many others – we were too optimistic in our expectations of economic growth. Exponential growth could not be achieved in the years after the millennium bubble and during the financial crises of the last years. Nevertheless the number of jobs in biotech companies has doubled in the last decade, and pharma giants like Bayer, Sanofi-Aventis and Pfizer have come to Berlin.

The BioTOP Report 2011 presents most recent developments in the region and an overview of the companies and research facilities located here. In 2010 companies returned to their accustomed growth levels again. After the economy had been more or less stagnant during the year 2009, the region is now showing splendid 4.7% growth – a clear sign of the region's economic dynamism. In terms of scientific and technological progress there are many encouraging developments, especially in the fields of diagnostics, drug development, regenerative medicine and industrial biotechnology.

BioTOP is proud to support this development as the central network node and your first contact. Based on our expertise, our direct contacts with industry and academia and our extended network we are continuously servicing the biotech industry in all questions regarding infrastructure, financing, tech transfer, human resources and business development. We would like to thank everyone whose commitment has contributed to making Berlin-Brandenburg a hotspot where scientific excellence drives economic growth, not just in biotechnology but in many other areas of our young knowledge-based industry.

We welcome everyone with ideas, plans and visions, personal ambition and a desire to play a part in the success of this great region. Feel free to get in touch with us any time!

Dr. Kai Bindseil
Director BioTOP Berlin-Brandenburg

A Reputation for Excellence in Life Sciences

The exceptional research community remains a strong driving force in the development of Berlin-Brandenburg as a biotech location. With more than 200 research facilities, Berlin is the capital of German science. The great tradition of this place of research became especially evident in 2010, when the city arranged a whole year of celebrations on the occasion of the anniversaries of five of its oldest and most prestigious science establishments.

The Berlin State Library commemorated its foundation 350 years ago. Charité – Universitätsmedizin Berlin commemorated its birth in 1710. The Berlin-Brandenburg Academy of Sciences celebrated its first statute of the same year and its opening in 1711 and Humboldt-Universität zu Berlin its founding 200 years ago, while the Max Planck Society commemorated the foundation of its predecessor organisation, the Kaiser Wilhelm Society, in 1910.

The Charité is now one of Europe's largest university hospitals. Some 3,000 doctors and scientists research, heal and teach here to the highest international standards. More than half of German Nobel Prize laureates for medicine and physiology have come from the Charité. The university hospital is held in the highest regard worldwide for its excellence as a site of academic teaching. With its 14,500 employees, Charité earns revenues of approximately one billion Euros per annum, making it one of Berlin's biggest employers. The pronounced entrepreneurial orientation of the Charité was underscored in 2010 by the closing of a cooperation agreement with Sanofi. As a partner for research and clinical tri-

als, the Charité is indispensable to the development of the biotech industry in the Berlin-Brandenburg region.

German Center for Cardiovascular Research

In spring 2011 it was decided that Berlin will be part of the new German Center for Cardiovascular Research (DZHK). The Charité, the Max Delbrück Center for Molecular Medicine (MDC) and the Deutsches Herzzentrum Berlin (DHZB) will combine their research in the DZHK under the name "Cardio Berlin". Associated partners are the German Institute for Human Nutrition in Potsdam-Rehbrücke (DIfE), as well as the Robert Koch Institute (RKI) in Berlin. The successful Berlin application was co-ordinated by Prof. Vera Regitz-Zagrosek, director of the Institute for Gender Research in Medicine at the Charité.

Cardio Berlin will be a novel integrative institution for basic clinical and public health research with a mission to maintain cardiovascular health throughout life by preventing disease and its progression. Cardio Berlin will combine existing basic research

News

February 2010

- German Medical Innovation Prize 2009, endowed with € 100,000, goes to Professor Dr. Ulrich Speck of the Charité

March 2010

- ground-breaking ceremony for new research building of Experimental and Clinical Research Center in Berlin-Buch
- Analytica Research Prize for Dr. Matthias Selbach of the MDC
- Potsdam Center of Systems Biology positively evaluated by the BMBF/ further support to 2011

April 2010

- Jiang Gao, PhD student at the Institute of Biochemistry, Free University, is the third winner of the Speed BIONNALE Lecture Award
- Construction of the Application Center for Polymer Nanotechnologies at the Fraunhofer Institute for Applied Polymer Research IAP in Potsdam-Golm starts

May 2010

- Centre for Biomaterial Development in Teltow and Tianjin University to start German-Chinese cooperation for the development of biomaterials for regenerative medicine.
- Dr. Joachim Storsberg from the Fraunhofer Institute for Applied Polymer Research (IAP) receives Joseph von Fraunhofer Prize

June 2010

- Bioanalytics researcher Janina Kneipp of BAM receives 1.39 million € ERC Starting Grant

July 2010

- Foundation stone laid for new research building of MDC and the Charité Campus Berlin-Buch
- Promotion Prize of the Berlin Scientific Society to Dr. Christel Bonnas of Excellence Cluster NeuroCure

September 2010

- Maria-Magdalena Titirici of the Max Planck Institute of Colloids and Interfaces receives 15th Desty Award for Innovation in Separation Science

October 2010

- 2. World Health Summit in Berlin
- Dr. Manel Esteller receives the World Health Summit and Pfizer Award for Innovation and Biomedical Research, endowed with 75,000 €
- Alzheimer's researcher Gerd Multhaup, Professor of Biochemistry at the Free University, is awarded the "Copper Award 2010" by the International Copper Association
- Matthew Poy and James Poulet from the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch and the Charité, receive research funds amounting to around 1,5 million € each from the ERC (European Research Council) for the next five years

Prof. Dr. Andreas Möglich

in the Institute of Biology at Humboldt-Universität zu Berlin will conduct research in the German capital for the next five years as a winner of the Sofja Kovalevskaja Award.

**Excellent Conditions for Research**

» When I felt the desire to return to Germany after an extended stay in the USA, I looked for programmes which would permit me to build up an independent working group at a German research institute. In particular the Emmy Noether Programme of the German Research Foundation (DFG) and the Kovalevskaja Programme of the Alexander von Humboldt Foundation, which is funded by the German Federal Ministry of Education and Research, finance projects of this kind. I applied successfully with the support of Prof. Peter Hegemann and Humboldt-Universität as the host institution and have now been in Berlin since summer 2010. The city provides an outstanding environment for my field of research: optogenetics.

on myocardial, vascular and metabolic mechanisms of cardiovascular diseases with systematic consideration of lifestyle, age, gender and ethnicity for more effective cardiovascular prevention. Interventional and preventive cardiologists will work together with surgeons, basic scientists and public health experts in an interdisciplinary institute. Extramural partners include industrial, healthcare and insurance companies. The DZHK will be financed by 90 % from central governmental funds and by 10 % by regional governmental funds.

Federal Funding (BMBF) for R&D projects**... in research institutions**

	per capita funding (euro)
Berlin	61,78
Mecklenburg-Vorpommern	38,84
Sachsen-Anhalt	30,15
Baden-Württemberg	27,71
Hamburg	26,37
Sachsen-Anhalt	25,33
Thüringen	22,7
Schleswig-Holstein	22,66
Saarland	20,06
Bremen	18,21

... in the life sciences at German universities

	projects	mio euro
Charité – Universitätsmedizin Berlin	168	92
University Freiburg	117	57,4
University Heidelberg	141	48,6
University Kiel	65	43,7
LMU München	132	43,6
University Leipzig	65	43,2

Figures for 2005–2009, source: ConsulTech GmbH, 2010

November 2010

- The Leibniz Institute for Molecular Pharmacology (FMP) in Berlin receives 3.7 million euros from the European Union for a three-year preparation phase of the EU-OPEN SCREEN project.
- Sofya Kovalevskaya Prize 2010 winners in the field of biotechnology, Dr. Dmitry Volodkin and Dr. Isabel Bäurle establish research groups at the Potsdam University.
- Prof. Ulrike Stein of the MDC receives Monika-Kutzner Prize for Cancer Research

December 2010

- Topping-out ceremony at the Biomedizintechnikum II at the Center for Biomaterials in Teltow

January 2011

- Prof. Andreas Radbruch of the German Rheumatism Research Center Berlin (DRFZ) receives Advanced Grant of the European Research Council (ERC) in the amount of 2.5 million €.
- Prof. Klaus Rajewsky receives Advanced Grant of the European Research Council (ERC) in the amount of 2.5 million € and establishes working group at the MDC

February 2011

- ESGL project (the European Sequencing and Genotyping Infrastructure), coordinated by the Max-Planck-Institute for Molecular Genetics, starts.

March 2011

- Charité-scientist Andrea Ode of the Julius Wolff Institute wins BIONNALE Speed Lecture Award.
- Prof. Oliver Daumke from the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch receives "Bayer Early Excellence in Science Award 2010" for biology.

April 2011

- Berlin research consortium becomes part of the German Center for Cardiovascular Research (DZHK)
- Dr. Daniel Toben of Charité receives Raisz-Dresner-Award of the American Society of Bone and Mineral Research (ASBMR)
- BioTOP and BCRT publish technology report on Regenerative Medicine in Berlin-Brandenburg
- Prof. Jan Schwab of the Department of Neurology at the Charité and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) received the Novartis Award for therapy relevant pharmacological research.

Prof. Karl Max Einhäupl
Chairman of the Executive Board
Charité – Universitätsmedizin Berlin



A unique European infrastructure for sequencing and genotyping

The Max Planck Society is also extremely active in Berlin-Brandenburg. Its Max Planck Institutes for Molecular Genetics, Infection Biology and Molecular Plant Physiology belong to the world's leading facilities in their respective fields.

In February 2011, a consortium of leading European research establishments began to build a European infrastructure for genome sequencing and genotyping. The project ESGI (European Sequencing and Genotyping Infrastructure) is being coordinated by the German Max Planck Institute for Molecular Genetics and funded by the European Commission under the auspices of the Seventh Framework Programme for Research and Technological Development. The participating institutions come from Austria, France, Germany, Spain, Sweden and Britain. The ESGI is to enhance Europe's position as a leading force in global genetics, genome research and molecular biology. The ESGI infrastructure will combine the efforts of leading European institutions in the fields of biology and bioinformatics to ensure that the broader research community can access genetic data and use the newest analytical tools. The aim is to permit scientists from all disciplines to use state-of-the-art technologies to decode complex gene functions at economic cost. Following the establishment of the infrastructure scientists will be able to sequence a genome for only app. 1,000 Euros.



Aaron Motsoaledi
Minister of Health of South Africa, at the World Health Summit 2010

Charité as an Entrepreneur

» The motto of the Charité is: "We bring the best medicine to the hospital bed". Continuous advances in science and technology offer many opportunities for fundamental changes in patient therapy. At the Charité, where doctors and scientists conduct research at the most advanced international level, we want to accelerate the introduction of the results of this research into patient care. This is why we have set ourselves the strategic goal of becoming the leading partner of the medical and pharmaceutical industry in Germany. With cooperation partners like Sanofi-Aventis or Novartis we are already implementing new concepts for cooperation between research establishments and industry. This new culture of exchange is in our mutual interest. Our partnerships will speed up joint product development based on our strong university hospital research.



Winner of the BIONNALE Speed Lecture Award 2011: Andrea Ode from the Julius Wolff Institute for Biomechanics and Musculoskeletal Regeneration, with Dr. Kai Bindseil, director of BioTOP



Detlev Ganten
President of the World Health Summit



Prof. Dr. Vera Regitz-Zagrosek
Director of the Institute of Gender in Medicine (GiM)
Charité – Universitätsmedizin Berlin

Cardiovascular Research Expands

» Berlin plays a key role in the newly founded German Centre for Cardiovascular Research (DZHK). The Charité, the German Heart Institute Berlin (DHZB) and the Max Delbrück Centre for Molecular Medicine will combine their cardiovascular and metabolism research under the name "Cardio Berlin" within the DZHK. Cardio Berlin is focusing on prevention and also plans to research gender differences between men and women in cardiovascular diseases. Clinical experts and researchers in a wide range of disciplines are working together here and applying state-of-the-art molecular genetics methods and imaging processes as well as holistic approaches (systems biology).

World Health Summit

Under the patronage of German Federal Chancellor Angela Merkel and French President Nicolas Sarkozy Charité – Universitätsmedizin Berlin organised the World Health Summit in cooperation with the M8 Alliance of Academic Health Centres and Medical Universities. For the second time this summit of leading representatives from medicine, science, politics, business and civil society convened to discuss the major challenges in medical research and healthcare and develop strategic solutions. The World Health Summit published results and recommendations which are made available to deciders in politics, science, research and the healthcare systems. It provided a unique opportunity to meet leading international personalities who are shaping medicine, research, health policy and global health strategies around the world. The objective in the many different discussions at the summit was to develop convincing and up-to-date core messages for the development of the innovation capacity of medicine and for tackling key global health challenges.

For 2011, the World Health Summit under the motto "Today's Science – Tomorrow's Agenda", will focus on non-communicable diseases and the role of mass media in health promotion, new approaches in research and innovation, ensuring public health in times of climate change and innovative models in global health governance.

FINANCING AND ADDED VALUE

VC Fonds Technologie Berlin

Venture Capital for companies in Berlin

IBB Beteiligungsgesellschaft mbH offers equity financing for high tech companies in Berlin. For our fund **VC Fonds Technologie Berlin** (€52m) we are looking for investment opportunities in the biotechnology and medical technology sector.

Our investment approach is based on hands-on involvement and active management support for each portfolio company, delivered by our highly experienced investment team. **VC Fonds Technologie Berlin** not only provides capital, but also helps execute the business plan.

Are you interested? Please do not hesitate to contact us.

IBB Beteiligungsgesellschaft mbH
Mrs. Ute Mercker / Mr. Christian Seegers
Bundesallee 171
10715 Berlin / Germany
Phone: +49 (0)30 2125-3201
www.ibb-bet.de

 **IBB**
Beteiligungsgesellschaft
Ein Unternehmen der IBB

Selected portfolio companies:



VC Fonds Technologie Berlin was set up as a joint initiative of Investitionsbank Berlin (IBB) and the State of Berlin. It is co-financed by the European Regional Development Fund (ERDF).



Biochrom AG

Biochrom AG is a company dedicated to be a primary supplier of cell culture media and quality animal sera.

The company manufactures and distributes the full range of products related to mammalian cell culturing technique: standard cell culture media, complete media tailored for particular cell types and cell lines, custom formulations, and animal sera, such as Fetal Bovine Serum (FBS). All sera are prescreened prior to acceptance; only those lots that meet strict quality control requirements are accepted for further processing and



subsequent sale to customers. Serum products are tested for sterility, adventitious viral agents, physico-chemical parameters, and biological performance. The manufacturing processes are designed for the specific needs of customers engaged in biotechnological research, development, and biopharmaceutical production. Biochrom AG specializes in meeting customers' specifications and regulatory concerns, to facilitate the manufacture of custom media consistent with Good Manufacturing Practice (GMP). The media are produced in a strictly controlled environment; chemicals used conform, where applicable, to grade standards of European Pharmacopoeia and US Pharmacopoeia. Biochrom AG produces lot sizes of sterile industrial buffers up to 4,000 litres, sterile media up to 2,000 litres, powder media up to 20,000 litres and customized sizes in smallest quantities.



Biochrom AG and TPP Techno Plastic Products AG (Switzerland) are exclusive partners for the sale of TPP products for cell culture and general laboratory equipment in Germany.

Address

Biochrom AG
Leonorenstraße 2-6
12247 Berlin · Germany

Phone +49 30 779 90 60
Fax +49 30 771 00 12
info@biochrom.de
www.biochrom.de



Bioline

Bioline is a primary manufacturer and developer of a wide range of molecular biology products. Our manufacturing sites are ISO 9001:2008 certified and strive to continuously improve the excellence of operational routines and quality assurance system. All stages of the manufacturing process are controlled and monitored by stringent quality control procedures to guarantee the highest quality and lot-to-lot reproducibility.

We strive to maintain close contact with our customers, key partners and collaborators to keep us at the forefront of new application areas and technologies providing feedback to our R&D groups and leading to new sustainable solutions for the bio-research reagents market.

When your requirements are beyond the scope of our standard product range we invite you to take advantage of our bulk, custom and OEM service.



For the last 19 years we have been providing custom made solutions to industrial and bulk partners and welcome new partners with specific product needs.

Our products

- Real-Time PCR Kits for standard and FAST cycling conditions
- DNA Polymerases and Mixes
- Reverse Transcription
- Cloning Reagents
- Nucleic Acid Isolation Kits
- Ultra-Pure Nucleotides
- DNA MW Markers
- Competent Cells
- Essential Reagents for molecular biology

Address

Bioline GmbH
Im Technologiepark TGZ II
14943 Luckenwalde

Contact

Holger Berthel
Sales Manager Germany
Phone +49 160 90144316
Fax +49 3371 681244
www.bioline.com
info.de@bioline.com



A Meridian Life Science® Company

ORGANOBALANCE GmbH

In Harmony with Nature

ORGANOBALANCE is specializing in microbial strain development and screening. The company taps into the potential of beneficial microorganisms, known as specific probiotic cultures, to compensate imbalances in the microflora and restore the microbial equilibrium. In close cooperation with leading industry partners ORGANOBALANCE develops new



biological products in the areas of nutrition, cosmetics and preventive health care. In its development activities, the company draws on its own collection of microorganism strains suitable for food applications and its OASSYS® screening systems.

Using innovative screening technologies and individually configured test designs, those strains of microorganisms are filtered that match application-specific criteria. For suitable strains, fermentation and downstream processes are developed in a pilot scale production facility.

In a long-term partnership with leading international companies ORGANOBALANCE developed marketable strains of probiotic cultures that combat tooth decay, body odour and skin irritation on a natural basis. Own product developments are pursued. Examples of targets

include gastrointestinal health and microorganisms with preservative effect. ORGANOBALANCE has a comprehensive knowledge and experience in the field of industrial biotechnology and develops strains by means of metabolic engineering.

Address

ORGANOBALANCE GmbH
Gustav-Meyer-Allee 25
13355 Berlin · Germany

Contact

Dr. Christine Lang · CEO
Phone +49 30 46307200
Fax +49 30 46307210
info@organobalance.com
www.organobalance.com



ORGANO BALANCE

PAREXEL International GmbH

PAREXEL International is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical phar-

macology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,380 employees.

PAREXEL has a long-standing presence in Berlin, where over 1,500 employees are located. Clients can benefit from state-of-the-art technologies and equipment provided through PAREXEL's medical imaging lab and Early Phase Units, which provide a safe, high-quality environment for early phase development activities in a hospital setting. The PAREXEL Academy located in Berlin qualifies clinical research associates and clinical data managers, and offers a

course for a Bachelor of Science degree in Clinical Research, validated by a British university.

Address

PAREXEL International GmbH
Klinikum Westend · Haus 18
Spandauer Damm 130
14050 Berlin · Germany

Contact

Dr. Ulf Schneider
Senior Vice President and
Chief Administrative Officer
PAREXEL International
Phone +49 30 30685 115
Fax +49 30 30685 7115
ulf.schneider@parexel.com
www.parexel.com

PAREXEL
Right where you need us™



Exploring the Regenerative Potential of the Human Body

Regenerative medicine is one of the research areas that have developed particularly fast in recent years. The capital region has been one of the pioneers in the field in the 1990s and has since built up important institutions, notably the Berlin Brandenburg Center for Regenerative Therapies (BCRT) and the Regenerative Medicine Initiative Berlin-Brandenburg (RMIB).

The term regenerative medicine denotes the development and application of innovative medical therapies using biomaterials, cells and hybrid organs. This rapidly expanding interdisciplinary research field combines the methods of clinical medicine (e. g. orthopaedics, surgery, intensive and transplantation medicine) with molecular and cell biology (genomics, proteomics, stem cell research), chemistry and biochemistry, pharmacology as well as the engineering and materials sciences (biomaterials, bioengineering), bioinformatics, medical engineering and nanotechnology. Berlin Brandenburg has taken up the challenge to bring together these diverse research approaches in order to accelerate the development of new therapies.

Translational Research

The Berlin Brandenburg Center for Regenerative Therapies (BCRT) is a center for translational research of the German Federal Ministry of Education and Research, and a joint initiative of Europe's largest university hospital, the Charité, and Germany's largest research organization, the Helmholtz association. The program focuses on endogenous regenerative therapies and is putting particular emphasis on research and clinical programs related to musculoskeletal, cardiovascular and immunological applications, since these aspects of regenerative medicine are most advanced at the Charité and closest to clinical translation. These medical research fields are linked to overlapping platforms on basic, bio-materials, and translational research.



Prof. Dr. Roland Lauster

Director of the Department of Medical Biotechnology and Managing Director of the Biotechnology Institute at Technische Universität Berlin

Chips Instead of Animals

» In the coming years, we expect the legal environment to develop and generate strong demand for a reduction in animal experiments. Our Multi-Organ Bioreactor in chip format permits reducing the number of substances requiring animal testing significantly because all substances that prove toxic on the chip no longer need to be tested in animals.

The BCRT is located in a newly reconstructed building at the Charité Campus Virchow Clinic. It is host to 26 newly implemented research groups. 19 groups are funded by the German Ministry for Education and Research, four groups are funded by the Helmholtz Association and three by the Deutsche Forschungsgemeinschaft (DFG).

For the interdisciplinary training of young scientists in the field of regenerative medicine in 2008 the Berlin-Brandenburg School for Regenerative Therapies (BSRT) was established as a graduate school of the German Excellence Initiative. It offers outstanding training and research opportunities for doctoral researchers in the biological and engineering disciplines and for clinical scientists. In 2010 the BCRT has been positively evaluated by the German Ministry for Education and Research and therefore secured funding for another four years.



The Report "Regenerative Medizin in Berlin Brandenburg" (in German language) is available for download at www.rmib.de

Close links between science and industry

Based on early initiatives to promote networking between research groups in the field of regenerative medicine, the "Regenerative Medicine Initiative Berlin" (RMIB) was founded in 2003. Initially focused primarily on science, the network opened out to the corporate sector in 2007 and has concentrated since then on networking between scientists and industry as well as between companies in Berlin and Brandenburg.

Today the RMIB is supported by the BCRT and BioTOP. Its activities focus on the continued extension of the regional interaction and information network between science and industry. That comprises joint working groups between scientists and users, communication structures between the players in regenerative medicine, and between them and adjacent fields as well as regional political institutions, and location marketing.

In terms of content, cooperation is guided by the themes of the regional working groups, i.e. the research areas and applications of regional companies, the BCRT and other regional research facilities. Within these thematic areas, companies and working groups establish joint projects using the RMIB communication platform and implement them with funding from suitable – often regional – funding programmes.



Dr. Andreas Baltrusch
CEO · co.don AG

Regenerative Therapies Instead of Prostheses

➤ More than 4,000 patients with joint and spinal disc problems have already been treated with our autologous cartilage transplants – and the success quota is very high. We are currently conducting two clinical trials which are the precondition for the approval and hence also the marketing of tissue engineering products under new legislation in the European Union. They will enable us to gain a far larger market share with our autologous cartilage cell products whose use is already refunded by the health insurers in Germany.

The RMIB's most important communication tool is the "Treffpunkt Regenerative Medizin" as a discussion and event platform covering current developments. In addition, the RMIB organises other specialised and interdisciplinary meetings and conferences. In several working groups researchers and companies share their experiences regarding regulatory issues or reimbursement strategies.



Topping ceremony of the Biomedizintechnikum II at the Center for Biomaterial Development in Teltow in December 2010. The picture shows Minister Martina Münch (2nd from left), Helmholtz-Zentrum Geesthacht CEO Michael Ganss, Prof. Dr. Andreas Lendlein, director of the HZG Centre for Biomaterial Development and Vice Director of the BCRT.

co.don

co.don® AG is a public biopharmaceutical company, founded in November 1993, since 2001 listed on Frankfurt stock exchange. co.don® AG manufactures cell-based tissue engineering therapeutics of the highest purity and to the highest quality standards. Its products represent a revolutionary process in the biological replacement of damaged articular cartilage, intervertebral disc and bone by building up strictly autologous tissue without the involvement of any external carrier materials or additives. The application of the products may be minimally invasive or arthroscopic and so surgery and rehabilitation times significantly reduced for doctor and patient. Because no external materials are used, the risks of rejection, inflammation and infection are very slight.

co.don® AG is certified in accordance with DIN EN ISO 9001:2008. Furthermore, production, quality control and quality assurance have been certified in accordance with European Guidelines for Good Manufacturing Practice (EU-GMP) since 1997. In 1997 co.don® AG was the first biopharmaceutical company in Europe to be granted a permit for the manufacture of autologous chondrocyte and osteoblast transplants under section 13 of the German Drugs Law (AMG).

co.don® AG's technological, production and regulatory expertise makes the company a first mover in the market for biological cartilage and bone replacement and a provider of highly effective, safe treatment options between pain therapy and endoprothetics.



Address

co.don AG
Warthestraße 21
14513 Teltow · Germany

Contact

Matthias Meißner, M.A.
Head Corporate Communications/IR/PR
Phone +49 3328 4346 0
Fax +49 3328 4346 43
info@codon.de · www.codon.de



Epigenomics AG

Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. Epigenomics' products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics' lead product, Epi proColon®, is a blood-based test for the early detection

of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A. The product portfolio further includes Epi proLung®, a confirmatory test aiding in the diagnosis of lung cancer that is marketed in Europe, and further products in development for colorectal, lung and prostate cancer. Epigenomics technology and products

have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international company with operations in Berlin, Germany, and Seattle, WA, U.S.A.

For further information please visit www.epigenomics.com

Address

Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin · Germany
Phone +49 30 243450
Fax +49 30 24345555
contact@epigenomics.com
www.epigenomics.com




—finding cancer early
epigenomics

Is the future *saccharomyces cerevisiae*?

At the beginning, only one entrepreneur recognised the potential behind this idea. He implemented this with determination and thus shaped the future.

The implementation of entrepreneurial ideas requires courage and determination. This requires a healthy financial foundation. That's where we come in. We create the financial preconditions for your entrepreneurial success. Together, we are shaping the future for people and business in Berlin.

Please contact us. Phone: +49 (0) 30 / 2125-0



Performing for Berlin.

www.ibb.de

* is the Latin term for baking yeast.

In Vitro-Diagnostics for the World Market

Berlin-Brandenburg provides exceptionally broad expertise in the fields of bioanalytics and in vitro diagnostics in a large number of high performing companies and research institutions. More than 20 research facilities conduct basic and applied research that helps to identify new biomarkers and develop assays and platform technologies for diagnostic tools. More than 80 companies in the field are engaged in the development of innovative technologies and products covering a broad spectrum of themes.

Specific and reliable diagnostics can make a major contribution to the prevention and treatment of diseases. Given the challenges facing our health system today, it is therefore of considerable importance. Bioanalytics includes all methods presently applied in biochemistry and molecular biology to investigate biologically active substances. In vitro diagnostics uses these and other methods to analyze human body fluids, cells or tissue outside the body and provide information that can then be used for the early detection and diagnosis of diseases and for monitoring disease progression and therapeutic success. In vitro diagnostics has grown in importance considerably in line with our increased ability to identify risk factors and serves as the foundation for decisions regarding the adoption of preventive measures. In vitro diagnostics therefore plays a central role in both out- and in-patient care and in preventive medicine.

Berlin-Brandenburg covers the entire breadth of research, teaching and patient care in the field of in vitro diagnostics. The clinics in the region also offer a broad patient collective for the implementation of clinical studies to validate biomarkers, consisting of urban and rural populations and a wide range of patients of international origin and presenting virtually all indication fields relevant to the development of marketable diagnostics. The region therefore provides the full value chain from research to product development. This is why the development of innovative diagnostics has been a key focus area of the innovation policy master plan of Berlin and Brandenburg since 2005.

In 2007 DiagnostikNet-BB was established as a network of diagnostics companies and research institutes as well as users at clinics and medical laboratories. It serves as a source for the launch of new joint R&D projects and as an information platform (www.diagnostiknet-bb.de).

Innovative food analytics

» In 2010 we purchased the molecular biological, PCR-based food safety test product line of the Berlin company ifp Institut für Produktqualität GmbH. The quality of their assays and their manufacturing expertise make ifp an ideal partner for us. Their testing technologies excellently complement our workflow solutions from sample to result, as well as our existing overall product portfolio in the field of applied testing.



Dr. Sandra Luley


Global Marketing Manager for Applied Testing · QIAGEN

In 2008 the Center for Molecular Diagnostics and Bioanalytics (ZMDB) has been established as a Flagship Project of the Joint Innovation Strategy Berlin-Brandenburg. The ZMDB serves as the platform for integration of regional expertise in basic research, technology development, clinical research and industrial applications. Its activities are guided by the Fraunhofer Institute for Biomedical Engineering (IBMT), Charité – Universitätsmedizin Berlin and companies in the region. (www.zmdb.de)

New European IVD Initiative

Europe concentrates substantial scientific and industrial critical masses in the field of medical diagnostic. This domain covers a large range of activities, from academic research to development, production of in vitro diagnostic tests, and innovative ways to introduce new IVD technologies into healthcare. The trend toward personalized medicine and translational research will foster more than ever the expectations of practitioners for specific in vitro diagnostic tests helping them in guiding their treatment decisions. This trend is also impacting the pharmaceutical industry that will have to deliver in the near future companion diagnostics to their innovative therapeutics.

In this context, the Center for Molecular Diagnostics and Bioanalytics (ZMDB) and other organizations from EU member states have founded the European Diagnostic Clusters Alliance (EDCA) that will help the European national players to become global leaders. EDCA partners include Euromediag, the diagnostic group of Eurobiomed cluster (France), Wal-Dx, the in vitro diagnostic group of the cluster BioWin (Wallonia - Belgium), Biocat (Barcelona, Spain), Life Science Cluster Krakow (Poland), Nexxus Scotland (UK), OBN (Oxford BioCluster, UK), Uppsala Bio (Sweden) and ZMDB (Berlin, Germany).



Dr. Andreas Weimann
COO
Labor Berlin – Charité Vivantes Services GmbH

20 Million Analyses per Year

➤ In 2011 Labor Berlin was founded as the service subsidiary of Europe's largest hospital laboratory for clinical pathology. The company offers complete solutions for any kind of testing and performs more than 20 million analyses per year. It is the exclusive laboratory partner of Charité – Universitätsmedizin Berlin and the Vivantes Network for Health and provides the diagnostics for approximately 9,000 in-house patients a day and over 800,000 out-patients per year.



At IFCC-WorldLab Berlin 2011, the major global event of Laboratory Medicine and Clinical Chemistry, in May 2011, more than 4,000 delegates discussed newest developments in diagnostics and laboratory medicine.

EDCA will help to identify and connect the "hot spots" of medical diagnostics players in Europe. Members will focus their partnership on fostering innovation through collaborative R&D projects and technological platform shares. Within these perspectives, cross-fertilization between different technological fields will be strongly encouraged.

LGC Genomics

LGC is an international science-based company and market leader in analytical, forensic and diagnostic services and reference standards. LGC Genomics is the division of LGC with specific expertise in high quality, cutting-edge genomic and related services and products. We offer a broad portfolio to a wide range of clients including pharmaceutical and biotechnology companies, private and public research organisations and medical institutions. Our quality management system is certified by ISO 9001:2008.

Address

LGC Genomics GmbH
Ostendstrasse 25 • TGS Haus 8
12459 Berlin • Germany
Phone +49 30 5304 2200
service@lgcgenomics.com
www.lgcgenomics.com

1. DNA sequencing services

- Single read sequencing
- Primer walking projects
- MTP sequencing (96/384 well)

2. Genomic services

- Next generation sequencing (Roche/454 and Illumina HiSeq 2000)
- Re-sequencing of genes and/or genomic regions
- Library services
- Cloning and sequencing
- Identification of microorganisms
- Genotyping services
- Pharmacogenetic services
- Bioinformatics services

3. Nucleic acid preparation

- 3.1. Automated DNA extraction
- Kits based on magnetic micro particles
 - Application of kits on different automated systems
 - Magnetic particle manipulators
- 3.2. Nucleic acid extraction service
- DNA, RNA (manual & automated)



Advancing genomic services and products

Tel: +49 (0)30 5304 2200
Email: service@lgcgenomics.com
www.lgcgenomics.com

© LGC Limited, 2011. All rights reserved.

Evestra GmbH



Evestra GmbH, founded in July 2008, is a fully owned subsidiary of Evestra Inc. located in San Antonio Texas. Evestra GmbH serves as the development and commercialization center for Europe and ROW. Evestra's mission is to develop and commercialize steroid-based female healthcare products.

The development strategy of the company includes product ideas with known compounds as well as New Chemical Entities.

Evestra is conducting research and product development in a number of in-demand, but as yet unmet, medical need areas of women's health such as hormonal-dependent breast cancer and endometriosis. The company is also pursuing different projects in fertility control, e.g. a new estrogen for oral contraception, with superior pharmacological properties compared to the standard drug ethinyl estradiol.

Several patents on new composition of matter, new technical processes and use patents have been filed during the last three years and support the strong intellectual property position.

Evestra is concentrating on R&D and will seek more partners for commercialization. More detailed information can be found on our web side.

Address

Evestra GmbH
Britzer Strasse 26
12439 Berlin • Germany

EU Contact

Prof. Klaus Nickisch • Managing Director
Phone +49 30 66509642
knickisch@evestra.com
www.evestra.com



BIOTECON Diagnostics GmbH

BIOTECON Diagnostics was founded in 1998 and currently has 50 employees. The company provides superior experience in microbiological service testing of food, pharmaceutical and cosmetics products.

The company's focus is the development of rapid and innovative detection systems for pathogenic, spoilage and genetically modified organisms (GMO) based on real-time PCR. The **foodproof**[®] product line includes detection kits as well as sample preparation kits for the extraction and purification of DNA from multiple food matrices.

As an international biotechnology company, BIOTECON Diagnostics has been developing, producing and marketing these products through a continually growing network of local distributors and worldwide sales channel partners.

Additionally the company offers the new **foodproof**[®] RoboPrep+ Series as the first commercially available system for automated food sample preparation and subsequent PCR setup. It has been developed as a cost-effective tool for food pathogen testing, reducing hands-on time and increasing lab efficiency.

Due to close contacts to many companies in the industry, BIOTECON Diagnostics is well aware of customers' current and future challenges. The company is able to provide flexible solutions to production and processing companies through new and economical approaches. Furthermore, BIOTECON Diagnostics also offers contract development and production to other biotech companies.

For safer food: BIOTECON Diagnostics – simply builds up trust.



Address


BIOTECON Diagnostics GmbH
Hermannswerder 17
14473 Potsdam · Germany

Contact

Kornelia Berghof-Jäger, Ph. D.
Chief Executive Officer
Alois Schneiderbauer
Chief Business Officer
Phone +49 331 2300200
Fax +49 331 2300299
bcd@bc-diagnostics.com



GILUPI GmbH



The **GILUPI** GmbH, founded in March 2006, develops, markets and sells innovative and new medical devices to detect and isolate rare blood cells, with a strong focus on the prenatal and cancer diagnostic market. The existing methods in the field of prenatal diagnostics bear the risk of miscarriage. The associated risk is about 1%.

Cancer diseases are detected relatively late. Biopsy procedures can therefore be

applied only in late stages of the disease. Currently there are no simple therapy accompanying examinations available.

The GILUPI product offers a minimally invasive application and a specific enrichment of certain cells from the blood stream. A subsequent diagnosis, in prenatal detection for example, allows the proof of chromosomal aberrations (e.g. trisomy). Compared to today's procedure, the detector can be used as early as in pregnancy week 10. In case of cancer diagnosis, a difference has to be made between the early diagnosis of a tumor and the monitoring of a cancer therapy. The GILUPI product will give access to higher numbers of Circulating Tumor Cells (CTC) compared to existing methods, by a percentage of over 80. The CTC can then be analyzed with existing tumor biopsy methods,

allowing an early personalized and optimized therapy.

Address

GILUPI GmbH
Am Mühlenberg 11
14476 Potsdam OT Golm · Germany

Contact

Klaus Lücke
Phone +49 331 58184782
Fax +49 331 58184780
info@gilupi.com
www.gilupi.com



Metanomics Health GmbH

Metanomics Health – a BASF Group company – applies comprehensive Metabolite Profiling (metabolomics) with biomedical data interpretation. Metabolite Profiling is defined as the parallel analysis of multiple endogenous and xenobiotic metabolites in biological systems. The core expertise of Metanomics Health resides in discovery and validation of biomarkers.

Technologies

- Metabolite profiling platform with more than 75 GC-MS and LC-MS/MS instruments
- Wide metabolite coverage via combination of unbiased and targeted platforms
- Unique tox mode of action prediction through MetaMap®Tox database
- Excellence in systems correlation analysis of complex gene function relationships

Major R&D-Topics

In cooperation with academic institutes and clinical experts Metanomics Health is running a large-scale diagnostic biomarker program. Areas include metabolic syndrome, heart failure, prostate cancer and multiple sclerosis to mention a few.

Market Segments

Metanomics Health provides its services to pharmaceutical, diagnostics and nutrition companies. Technology applications include:

- Mechanism of action studies
- Mechanism of toxicity studies
- Translational and clinical biomarker development (e.g. PK/PD, patient stratification, efficacy and safety markers)
- Companion diagnostic development
- Cell culture & bioprocess optimization



Address

Metanomics Health GmbH
Tegeler Weg 33
10589 Berlin · Germany

Contact

Dr. Tim Bölke
Managing Director
Phone +49 30 34807 400
Fax +49 30 34807 401
company.info@metanomics-health.de
www.metanomics-health.de

metanomicshealth



metanomics GmbH

Metabolite Profiling for plant biotechnology, drug development and diagnostics

Metabolite profiling uses the metabolism as sensoric level – equivalent to a physiological “dashboard” – to analyse and interpret the biological status of an organism. Metabolite Profiling is the parallel measurement and interpretation of hundreds to thousands of endogenous metabolites in a sample from plants, microbes, animals or humans. This unique and unbiased approach allows the observation of whole biological systems. metanomics has developed this technology for a wide range of applications and markets spanning the entire spectrum of biology.

metanomics operates by far the largest and leading Metabolite Profiling and Data Interpretation platform globally. metanomics technology is largely based



on a range of 75+ mass spectrometers spanning several technologies, supported and driven by bioinformatics and systems biology platforms. metanomics is part of the international BASF Plant Science research platform. The company is the discovery center for Plant Biotechnology research, Toxicology and Crop Protection at BASF. The platform also drives and supports Pharma, Nutrition and Diagnostics discovery as the technology backbone for metanomics Health.

Address · Contact

metanomics GmbH
Tegeler Weg 33 · 10589 Berlin · Germany
Dr. Arno Krotzky · Managing Director
Phone +49 30 34807 101
Fax +49 30 34807 301
company.info@metanomics.de
www.metanomics.de

metanomics 
new dimensions in discovery

ifp Institut für Produktqualität GmbH

Founded in 2004, ifp Institut für Produktqualität GmbH is an independent competence centre for food, feed and pharmaceutical analytics, offering a complete range of services. In addition, ifp develops and produces innovative products which are commercialized globally through a network of selected distribution partners. In its seventh business year, ifp currently employs 70 staff.

Food Analytics

The combination of expert staff, state-of-the-art laboratory equipment and products specifically developed by ifp guarantees high-quality analyses and competent service.

The portfolio includes:

- Allergens: qualitative and quantitative allergen analytics as well as allergen management consulting
- Vitamins: determination of all water- and fat-soluble vitamins
- Microbiology: microbiological and molecular biological detection of microorganisms in food and drinking water. Additionally, ifp offers hygiene management consulting.
- GMO: screening, identification and quantification of genetically modified organisms
- Mycotoxins: HPLC analyses covering the complete range of mycotoxins
- Nutritional value: analysis of the basic food components, e. g. water, fat, protein, carbohydrates etc.



Ifp also offers extensive auditing, quality assurance, and control services covering the entire production process. The ifp

Quality Seal is awarded to products that undergo and pass this examination.

Pharma Analytics

Ifp meets the highest demands not only in food analytics but also in the field of pharmaceuticals. The company has been GMP certified as per Section 14 (4) No. 3 of the German Drug Law, making it an official testing laboratory for subcontracted drug analyses in compliance with the Good Manufacturing Practice (GMP) guidelines. This authorizes ifp to carry out microbiological tests relevant for the release of pharmaceutical products. The services include testing for microbial purity of non-sterile medical products, testing for sufficient antimicrobial preservation and bacteria endotoxins, identification of microorganisms and analyses of water and monitoring samples.



Innovative Products

Several innovative product lines developed and produced by ifp are successfully distributed worldwide through renowned cooperation partners. The microtiter plate-based VitaFast® vitamin kits are distributed by R-Biopharm. In 2010, QIAGEN acquired the sales rights for ifp's real-time PCR kits for the detection of pathogens, GMO, and other parameters which are now available under the trademark *mericon*™. The AgraStrip® product line includes immunological lateral flow tests for the rapid

screening of allergens and is exclusively distributed globally by Romer Labs.



In March 2011, ifp officially launched its fourth product line within five years, EnzymeFast®. For this microtiter plate based test for the enzymatic determination of sugars, acids and other metabolites, ifp has been awarded the InterLabTec Award for Innovative Solutions for Analysis in Labs and Processing at the 1st InterLabTec Congress in Munich. More products are currently in the pipeline. Additionally, ifp is involved in several research projects.

Address

ifp Institut für Produktqualität GmbH
Teltowkanalstraße 2
12247 Berlin · Germany

Contact

Dr. Wolfgang Weber
General Manager
Phone +49 30 766860 0
Fax +49 30 766860 50
www.produktqualitaet.com
info@produktqualitaet.com



Excellence in Drug Discovery and Development

In the Capital region, both pharma and biotech industry are developing dynamically. Along with the emergence of new biotech companies an increasing number of international pharmaceutical companies are discovering the advantages of this region for their European operations and are extending their activities here.

By far the biggest pharmaceutical company in the region is Bayer HealthCare Pharmaceuticals. Its research is focusing on four areas: Cardiology & Hematology, Oncology, Diagnostic Imaging and Women's Healthcare. In 2010 Bayer HealthCare spent more than 2 billion Euros on R&D. BERLIN-CHEMIE AG, a subsidiary of the Menarini Group employs almost 3,000 people in Berlin. Sanofi, the sixth largest pharmaceutical company in the world, came in 1996 to Berlin and has since grown considerably. In 2010, a comprehensive research partnership was established with the Charité. Pfizer has its headquarters in Berlin since 2008. In 2010 B.Braun expanded its vials production capacities in Berlin with an investment of 20 Mio Euros. The company plans further substantial investments in the coming years. With approximately 10,000 employees, sales of the pharmaceutical companies in Berlin-Brandenburg were almost 6 billion Euros in 2010. Pharmaceutical industry is complemented by innovative biotechnology companies that have developed a number of novel therapeutic approaches in recent years, such as the next generation glycooptimized antibodies of Glycotope, NOXXON's therapeutic spiegelmers, the RNAi technology from Silence Therapeutics and the gene therapy of Mologen.

Well connected

An important prerequisite for the successful development of the region lies in the strong network of science and industry in drug development. That's why in 2007 the Leibniz Institut für Molekulare Pharmakologie (FMP) and BioTOP Berlin-Brandenburg established the Network for Drug Discovery & Development Berlin-Brandenburg as an open interdisciplinary initiative with the aim to accelerate the transfer of clinical relevant findings into innovative drugs and therapeutic concepts. The network guides researchers through the highly complex process from target discovery to the point of preclinical development of drug candidates and helps locating resources needed in each phase. This ranges from the initial high throughput/high content screening (HTS/HCS) during the assay development phase to the development of a drug candidate. The latter is usually sponsored by the pharmaceutical industry due to the significant commitment in terms of costs, resources, and time.

Berlin Region Positioned Excellently

» Medical biotechnology offers tremendous potential for providing severely diseased patients with new therapy options for which there is still high medical need. Biopharmaceuticals have already shown impressively during recent years how effectively they can help patients. To ensure that the innovation and investment motor of medical biotechnology keeps running smoothly in future, however, innovations must also be rewarded adequately and reliably. And that requires dialogue between all stakeholders in the healthcare sector. The Berlin-Brandenburg region is certainly in an excellent position to play a leading role in health research and biotechnology and make a strong contribution in the interest of patients and for our region.



Dr. Sabine Sydow

Head of vfa bio, interest group for biotechnology within the German Association of Research-Based Pharmaceutical Companies



Dr. Matthias Schroff

Head of Research and CEO, MOLOGEN AG

The network's coordination office is located at the FMP in Berlin-Buch. Most of the current network partners – academic research institutes, universities and their associated medical facilities, as well as biotech and pharmaceutical companies – are located in Berlin and Brandenburg.

International cooperation

Cooperation at European level is becoming more and more important for large-scale research projects. Again, the region has major initiatives in the lead.

In November 2010 the preparatory phase of the EU funded research infrastructure EU-OPENSREEN started. EU-OPENSREEN, which is coordinated by the FMP, will draw together, in a common platform, the many individual European laboratories that are studying potential drug candidates. Information about the biological effects of chemical substances will be collected from across Europe, aligned to common standards, and made publicly available. The screening laboratories will thus form a network that extends beyond national borders and is accessible to other researchers. The EU considers this initiative among the most important international research infrastructures of the future. The centralized database created by the project will give researchers open access to everything that is known about a substance, obtained from a wide variety of experiments.

Novel approaches for identification of new markers for colon cancer

» OncoTrack is a prime example of the manner in which Public-Private Partnerships are breaking new ground in collaborative research involving academic and industrial partners. We have assembled a team of clinicians, molecular scientists, bioinformaticians and associated experts; thus creating a Europe-wide network of complementary capabilities extending far beyond the scope of a traditional 'one-on-one' industry-academic collaboration. The joint efforts of this consortium will generate the critical mass required to tackle the complex task of using large-scale genomic analysis as a basis for rational selection of novel cancer biomarkers.

Excellent Clinical Results

» With the proof of the active principle of the colorectal cancer medicine MGN1703 and the start of our clinical Phase II/III trial, MOLOGEN AG achieved important milestones in 2010. In addition to the two current clinical studies with MGN1703 and the renal cancer drug MGN1601, we will prepare a third clinical cancer study in 2011. Due to our successful capital increases we are positioned very well to conduct licensing negotiations and broaden our product pipeline considerably.

Consortium for genomic cancer biomarker development

In March 2011 OncoTrack, an international consortium of over 60 scientists, managed by Bayer HealthCare Pharmaceuticals and the Max Planck Institute for Molecular Genetics in Berlin, launched one of Europe's largest collaborative academic-industry research projects to develop and assess novel approaches for identification of new markers for colon cancer. The essential objective of OncoTrack is to establish new methods for systematic next generation oncology biomarker development. Detailed molecular characterization of high quality tumor tissue will provide critical information to support the fundamental understanding of cancer and the influence of heterogeneity on response to colon cancer therapy.

The project is partnered with a selected group of major global pharmaceutical companies, composed of AstraZeneca, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Janssen Pharmaceutica, Merck, Pfizer and Roche Diagnostics, whose in-kind contributions to the project are matched by funding from the IMI Joint Undertaking, resulting in a total budget of more than 25 Million Euros. Among the partners are also the Berlin based companies Epo and Alacris Theranostics as well as the Charité – Universitätsmedizin Berlin.



Dr. David Henderson

Principal Scientist in Translational Sciences at Bayer HealthCare Pharmaceuticals, and Coordinator of OncoTrack, an international consortium funded by the Innovative Medicines Initiative (IMI), a young and unique public-private partnership between the pharmaceutical industry and the European Union.

Glycotope GmbH

Glycotope has developed a unique and regulatory approved platform technology for the development and production of NBEs and improved second generation biopharmaceuticals / BioBettters. This toolbox of human cell lines allows the manifold improvement of key clinical properties (such as activity, availability, immunogenicity) for both antibodies and non-Ab proteins via targeted alteration of the glycosylation. With excellent production features, GlycoExpress is also the base of Glycotope's current late-stage pipeline of 4 therapeutic antibodies – two of which have entered the clinic in 2009 and 2010 with the

third to follow in Q2/2011 – and a non-AB protein-hormone scheduled to initiate clinical trials in H2/2011.

GlycoExpress

- Toolbox of glycoengineered human cell lines
- Fully human & optimized glycosylation
- Highly improved bioactivity, bioavailability & immunogenicity
- Screening and high yield production system
- Permits new patent protection of products

Pipeline of GlycoOptimized Products


- Proprietary NBEs & improved second generation BioBetter antibody and non-antibody products

Via Glycotope Biotechnology

- GMP-Production of biologics
- Fill & Finish of API and drug

Address

Glycotope GmbH
Robert-Roessle-Strasse 10
13125 Berlin · Germany
Phone +49 30 94892600
Fax +49 30 94892609
info@glycotope.com
www.glycotope.com



GLYCOTOP
The GlycoEngineering Company

caprotec bioanalytics GmbH

caprotec bioanalytics GmbH has developed a ground-breaking, proprietary technology to reduce the complexity of protein mixtures in a targeted and directed manner.

Founded in 2006 by scientist and entrepreneur Prof. Dr. Hubert Köster, founder of Sequenom Inc. and Biosyntec, caprotec raised approx. 9 million \$ in 2007 and 5 million \$ in 2010. Caprotec is operational in Berlin Adlershof since the beginning of 2008 and currently has 30 employees.

caprotec's Capture Compound Mass Spectrometry (CCMS) Technology is based on multifunctional small molecules that are used to target, capture, and isolate proteins based on their functionality. The company is commercializing the CCMS technology as kits for research applications and in the form of collaborations for drug development.



caproKit™ for the characterization of staurosporine binding protein kinases

In collaborations for drug development caprotec is using small molecule drugs or drug candidates to establish a profile of proteins that interact with the specific small molecule. The profile can be used to elucidate the mode of action of drugs and drug candidates and also to discover off-target proteins that are responsible for unwanted side effects, e.g. liver toxicity.

Address

caprotec bioanalytics GmbH
Volmerstraße 5
12489 Berlin · Germany

Contact

Dr. Christian Jurinke
Director, Product Management
Phone +49 30 63 92 3992
christian.jurinke@caprotec.com
www.caprotec.com

 **caprotec**
capture protein technology

Silence Therapeutics AG

SILENCE Therapeutics AG is the leading RNAi therapeutics company in Europe. The Company has developed novel, proprietary short interfering RNA (siRNA) molecules called **AtuRNAi** and proprietary systemic delivery systems for siRNA.

Strong IP Position

SILENCE's strong IP position is based on a broad portfolio of patents issued in the US, Europe and other territories.

Validating Pharma Partnerships

SILENCE has established validating partnerships with **AstraZeneca** (\$15m upfront payment & equity, \$400m milestone payments), **Pfizer/Quark** (\$95m milestone payments incl. upfront) & **Dainippon Sumitomo** (delivery collaboration) and **Novartis/Quark** (\$80m milestone payments incl. upfront).

prevent the formation of pulmonary metastasis in various animal models of cancer metastasis.

- **August 19, 2010** Novartis takes an option from Quark Pharma ("Quark") to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology (\$80million milestone payments for Silence).
- **July 14, 2010** Extension of the research collaboration and license agreement with AstraZeneca which started in 2007. Silence and AstraZeneca are jointly collaborating on the identification and optimization of five novel siRNA therapeutic molecules addressing respiratory and oncology indications.



a broad portfolio of intellectual property.

SILENCE Therapeutics AG, Berlin, is listed through its holding company SILENCE Therapeutics plc, London, at the Alternative Investments Market (AIM) of the London Stock Exchange.

Overview of AtuRNAi Programs

Products	Indications	Partners	Target	Delivery	Preclinical	Phase I	Phase II	Target Tissue/ Organ
PF-4523655	Age-related Macular Degeneration	Quark/Pfizer	RTP-801 (REDD1)	Naked siRNA				Local Delivery to the Eye
QPI-1002	Prevention of Delayed Graft Function	Quark/Novartis	p53	Naked siRNA				Systemic Delivery to the Kidney
QPI-1002	Acute Kidney Injury	Quark	p53	Naked siRNA				Systemic Delivery to the Kidney
Atu027	Solid Tumors (anti-metastatic)	Internal	PKN3	AtuPLEX				Systemic Delivery to Tumor Endothelium
Atu111	Acute Lung Injury	Internal	Ang-2	DACC				Systemic Delivery to Lung Endothelium
Atu134	Solid Tumors	Internal	CD31	AtuPLEX				Systemic Delivery to Tumor Endothelium
Atu150	Solid Tumors	Internal	p110	AtuPLEX				Systemic Delivery to Tumor Endothelium

Four Clinical AtuRNAi Programs

Out of 11 clinical siRNA programs worldwide as of April 2010 there are **4 clinical programs** (see table) with SILENCE's **AtuRNAi** molecules. These are SILENCE's internal lead program **Atu027** and three clinical study programs conducted by SILENCE's partners Pfizer and Quark. This underlines SILENCE's leadership in the field of siRNA therapeutics.

Internal Lead Program

SILENCE's internal lead program **Atu027** is currently in a **Phase I clinical study** recruiting patients with advanced gastrointestinal, lung and other solid cancer (21 patients enrolled as of February 2011).

Recent Corporate Highlights

- **November 10, 2010** Landmark publication in Clinical Cancer Research demonstrating the ability of Silence's siRNA drug candidate, Atu027, to

- **May-October 2010** Issuance of various patents by the United States Patent and Trademark Office and the European Patent Office.
- **April 21, 2010** Extension of the siRNA delivery collaboration with AstraZeneca which started in 2008. Under this collaboration a number of Silence's proprietary lipid delivery and targeting technologies are leveraged to develop new and enhanced delivery approaches for siRNAi therapeutics.
- **March 30, 2010** Expansion of the siRNA delivery collaboration with Dainippon Sumitomo Pharma which started in 2009 in order to examine additional disease targets.
- **January 5, 2010** Merger with US based Intradigm Corporation - The enlarged company now possesses multiple RNAi discovery, development and delivery technologies, an advancing internal and partnered product pipeline and

Address

Silence Therapeutics AG
Robert-Rössle-Straße 10
13125 Berlin · Germany

Contact

Thomas Christély
Chief Executive Officer
Dr. Klaus Giese
Chief Scientific Officer
Dr. Jörg Kaufmann
VP Research

Phone +49 30 9489 2800
Fax +49 30 9489 2801
www.silence-therapeutics.de
info@silence-therapeutics.com



Technologies for the Bio-Based Economy

While the prices of fossil raw materials are rising, the use of renewables must become cheaper. Biotechnology plays a central role here. And Berlin-Brandenburg is home to a great deal of the expertise needed to bring efficient processes for the industrial use of biomass to market maturity.

In view of global developments like climate change, population growth, the increasing scarcity of fossil energy resources and rising energy costs, the intelligent use of renewable raw materials – bio-economy – is becoming increasingly vital to solve important questions facing humanity.

In particular the combination of modern biomass production processes to deliver new bio-based products will offer important approaches for solving problems in global food supply, meeting global energy needs and reducing harmful emissions.

For Berlin and especially the land-rich state of Brandenburg, the knowledge-based bioeconomy presents major opportunities. Agricultural production, classic academic fields like agriculture and nutrition research as well as the new green and white biotechnology disciplines are all well represented here.

At the technology policy dialogue on “Biotechnology – Innovations and Sustainability for the Use of Renewable Raw Materials” in Potsdam in November 2010, participants from different areas of science, economic, agricultural and environmental policy discussed how Brandenburg can develop into a major bioeconomy location where new products and production processes can be researched, developed and implemented. In view of the region’s outstanding scientific resources and a remarkable range of specialised companies, the biotechnological use of renewable energies is to be a focus of development in the region in the coming years.

Exploiting the Potentials in the Bioeconomy

» In Brandenburg, we have both renewable raw materials and internationally outstanding research in the relevant fields. This endows us with the opportunity to develop products for the rapidly expanding world market in the still young and evolving bioeconomy segment using innovative technologies.



Prof. Dr. Hans-Peter Fink

Director of the Fraunhofer Institute for Applied Polymer Research (IAP) in Potsdam-Golm



Together with partners in industry and research, scientists at the Leibniz Institute for Agricultural Engineering in Potsdam-Bornim (ATB) have developed a process for the production of ultrapure lactic acid based on continuous process management. It uses renewable raw materials and achieves up to five times greater productivity than conventional discontinuous fermentation processes. The biotechnology processes developed at laboratory and technology centre scale are now being tested in a pilot production plant. With this scale-up, the circle from applied basic research to technical implementation at near-industrial scale is being closed.

AAT TGA CAC ACG TTC GCC GAT AAG GAA GTT ATG GAA CCT
GGA CCA TCA CGA TAA AAC GGA CAA TTA CCC GAT TGG AAA
ATC GAA ACC GAA TCA GCC AGT CAA GAA GCT TTC GAC TGC
GTA TTG CAA GGC CAC CAG TAG CAC ACG TGC GGA ACG ACA
TAA ACT GGA ACA AGA TCC AAA GCT TAT TGG AAG TGC CCG
CCA **STUDIES & CONSULTING** GCA TAC CAA TGC ATG CAC GGA
AGG TTC GTA TTA ACT AGA GAT CAT TCT AAC CCT TAT AGC
GTT **CONFERENCES** AAG GAG ATC CCC TTG ACC GGC CGG TTT
TCC CTC CTG GCG GTG TCA AAT CAG TGA CGA CCG TGT ACA
ACA **BOOKS** TC TCG CCA TAA CGT TGG CTT AAA GCT TAG GCC
GCC ACG GAA ACG GGT GAC GGG AAT CCA ACC GAC AGA ATT
TGA **TV & VIDEO** AC TCC GCA CAT TTG CGA GCT AGA ACG TAA
GCC TAG GCT CAA AAC GCA TGT GCC GAT CAA GAA TGC AAG
GAT **CORPORATE PUBLISHING** TTT GGA GAA CTA ACA TCT AGA
ATC CAG CTT ACC AGA TGC AAG ATC TTG GGA GGC ACT GAG
GTA **INTERNET** CTC CGC ACG TCC AAT GGA ATC GTA TAA CCA
AGG GTT TCC ACA GCC TGA GCC GAT ATC GTA AGG TGA CAA
GAA **MAGAZINES** GA TTC GTC CTC AGT ACG TCA TAG CAA ACT
CAC TCA ACC CAA GGA GTT GTA CTA CTG CGC GAA CTT ACG
CGA **EVENT MANAGEMENT** TA GCG TCG ACG CAC CAA TGC ACC
GCC AAC GCC CAG TCC ATT AGA GAG TCA TAA GAC GCA GCA
CAA CAC GCT GTT CCC GGA TGC ACA GCC AGG ACT CTT TGC
AGC GGC AAA GCA CAT CCA AGA GAA TGG GAC ACG TGC CAC
ACC GGC GCA TGT TGA CAC AAT CAG CCT GAT TAG CAC CAG
TAA GCT AGA CAA ACA TCT **WE CREATE KNOWLEDGE!** TGG
AGT GTT CTC AAG GAA TGA CGA TGT GCC TTG ACC TCG ACG
GTT ACT ACG TCC TGC ATG TTG CGA TTG GGA AGA AAA CTC

Returning to Growth

In 2010 companies in the Berlin-Brandenburg region returned to their accustomed growth levels again. After the economy had been more or less stagnant during the prior year, the region is now showing splendid 4.7% growth. Compared to the average growth rate of 3.5% in the preceding years, this is a very good result and a clear sign of the region's economic dynamism. Some 200 companies in the Berlin-Brandenburg biotechnology sector currently employ 3904 people.



Harald Wolf

Senator for Economics, Technology and Women's Issues and Mayor of Berlin

The Health Region Berlin-Brandenburg

» With more than 350,000 employees, the health economy is the largest and most developed cluster in the region. In the context of the joint innovation strategy of Berlin and Brandenburg, we established a cluster management in autumn 2010. An experienced team from institutions in the two states under the direction of Cluster Manager Dr. Kai Bindseil and Cluster Spokesman Prof. Dr. Günter Stock is ensuring that the sector continues to grow by supporting effective networking, technology transfer and project coordination in the core segments biotechnology, medical technology and pharmaceuticals.

Corporate development in 2010

As every year, BioTOP surveyed the companies in the cluster to analyse the current situation in the industry and provide a comprehensive overview of the corporate landscape in its database at www.biotop.de.

During 2010, 12 new companies were founded while 7 withdrew, so that the number of enterprises rose by 5 to the present total of 200. The corporate business models continued to follow the trend established during the preceding years. The companies founded are predominantly small with 1 - 10 employees and focused on service-oriented business models and near-market maturity developments. This is due primarily to the continuing lack of venture capital and the fact that investors have tended to focus more strongly on low-risk business models.

The newly founded companies include aevotis GmbH in Potsdam which has positioned itself very successfully as a partner for the food industry with its proprietary technologies for the conversion

News Wirtschaft

January 2010

- Silence Therapeutics acquires U.S. company Intradigm, € 17 million capital increase

March 2010

- Epigenomics AG: € 33 million capital increase
- At CeBIT 2010 Medipan receives the IT Innovation Award of the Initiative Mittelstand for AKLIDES, a fully automated system for the evaluation of cell-based immunofluorescence tests

April 2010

- First "German Biotech Days" with 600 participants in Berlin
- Silence Therapeutics extend siRNA delivery collaboration with Astra-Zeneca and Dainippon Sumitomo

May 2010

- NOXXON announces the completion of first-in-human clinical trial with Spiegelmer NOX-A12 and raises € 33 million in Series D Round
- The "25 Prix Veuve Clicquot" for the Businesswoman of the Year goes to Alexandra Knauer
- Caprotec Bioanalytics closes \$5M funding round
- The Charité - University Medicine Berlin and sanofi-aventis sign landmark agreement on cooperation in research
- ifp Institut für Produktqualität enters global cooperation with QIAGEN to market its food tests
- MagForce Nanotechnologies AG secures financing up to € 20 million through an equity line

June 2010

- MOLOGEN AG starts phase II clinical study with DNA-based cancer medicine MGN1703 against colorectal cancer
- Minapharm Pharmaceuticals acquires majority stake in ProBioGen - Dr. Wieland Wolf appointed new CEO
- MagForce Nanotechnologies receives European regulatory approval for its Nano-Cancer(R) therapy
- Signature Diagnostics AG announces positive results for its in-vitro diagnostic screening test for early detection of colorectal cancer

July 2010

- Epigenomics AG: Licensee ARUP launches Septin9 colorectal cancer blood test in the United States
- Silence Therapeutics and Astra-Zeneca extend siRNA development collaboration
- First brain tumor patient treated with IsoSeed® from Eckert & Ziegler
- Epigenomics AG launches diagnostic lung cancer test in Europe
- NOXXON to initiate Phase Ib clinical trial of MCP-1 inhibitor NOX-E36
- BIOTECON Diagnostics and Xiril AG start worldwide marketing alliance

Number of Employees according to Company Size



In comparison to the previous year, the average number of employees per company got reduced by 2% in the 1-10 category and increased by 2% in the 11-50 category. The average number of employees in the category > 50 employees decreased by 8%. (Source: Own survey, BioTOP database, 200 companies questioned, February 2011)

August 2010

- GlycoTope starts phase I clinical trial with glycooptimized antibody CetuGEX™
- MerLion Pharmaceuticals completes US\$ 7 million series C financing round

September 2010

- Co.don's autologous cell therapy used for the first time in arthros-copic cartilage defect of the hip joint. Brandenburg Investment Bank approves € 2.5 million funding for co.don AG

October 2010

- GA Generic Assays GmbH receives business award 2010 of the Chamber of Commerce and Industry (IHK) Potsdam
- MicroDiscovery and Bayer Schering Pharma prolong successful cooperation

November 2010

- ProBioGen presents GlymaxX - The Novel Glyco-Engineering Technology
- MagForce and GlycoTope are amongst the winners of STEP Award 2010
- BioGenes has developed Cellmid's Midkine blood test and reports manufacture of first kits

December 2010

- ORGANOBALANCE Medical AG starts business operations
- GlycoTope receives Innovation Award Berlin Brandenburg 2010
- Source BioScience Group (UK) acquires imaGenes GmbH

January 2011

- RNL Bio (Korea) acquires the Berlin stem cell company Pharmicell Europe
- QIAGEN to acquire stake in Alacris, gaining access to biomarker pipeline for use in personalized healthcare assays
- GILUPI GmbH: VC funding in the amount of € 3.6 million

February 2011

- MOLOGEN AG: € 10 Mio capital increase
- The European Commission awards the newly created "Region of Excellence" label to Brandenburg

March 2011

- Algenol announces acquisition of Cyano Biofuels GmbH
- Revotar Biopharmaceuticals meets primary endpoint in Phase II COPD study with inhaled Bimosiamose

April 2011

- Co.don AG: exclusive agreement with Novomedics GmbH to distribute its cell-based therapy chondro-sphere® for Switzerland
- GlycoTope Biotechnology expands GMP production facility to 11 kg antibody per year and starts phase I clinical trial of FSH-GEX for the treatment of anovulatory infertility

May 2011

- Lonza and ORGANOBALANCE enter global license agreement to develop and market unique probiotic (Lactobacillus anti-H. pylori)

Dr. Peter Heinrich
CEO · MagForce AG



MagForce Receives the STEP Award 2010 as Winner in the Category "Products/Technology"

» We are very proud to have received the renowned STEP Award in recognition of our innovative MagForce therapy for the treatment of brain tumours. This new therapeutic approach uses nanoparticles which are activated by our magnetic field applicator to generate heat within the tumour. Our marketing and sales organisation is now working to ensure that patients will have access to our innovative NanoTherm® therapy at leading cancer centres in Germany.

of raw plant materials into superior carbohydrate products, and Alacris Theranostics which applies state-of-the-art technologies to analyse the tumour material of individual cancer patients. One of the Alacris investors is QIAGEN who acquired options to all biomarkers discovered by Alacris as a result of its investment.


Deals and new products

The year 2010 was marked by a number of new cooperative ventures and important milestones in product development. We present a selection of examples from the wide range of entrepreneurial activities in the Berlin-Brandenburg biomedicine and biotech sector:

Epigenomics AG reported several deals closed in 2010 to intensify global marketing of its molecular diagnostic cancer tests which are based on the determination of changes in DNA methylation. The transactions included a non-exclusive license agreement with QIAGEN for commercial use of the company's test for blood-based diagnosis of colorectal cancer and an agreement with the company ARUP Laboratories which plans to launch the same test on the US market.

Silence Therapeutics, a leading company in the field of RNAi therapy development, was also very active, acquiring the US company Intradigm and thereby expanding its siRNA delivery range. In addition, Silence extended its cooperation agreement with Astra Zeneca and expanded its delivery cooperation with Dainippon Sumitomo.

Employees in Biotech SMEs



Employment rose to 3904 in 2010. The number of companies went up to 200, reflecting the arrival of twelve companies and seven departures. (Source: Internal survey, BioTOP database, 195 companies questioned, February 2011)



Since its successful launch in 2007, the Charité Entrepreneurship Summit has become an annual international forum for participants and speakers coming from various professional backgrounds in medicine, the life sciences, and in entrepreneurship. 2010 Summit Dinner was held at the Museum for Communication Berlin.



Dr. Claire Skentelbery
Network Manager of the Council
of European BioRegions (CEBR)

An integrated international network

» The Council of European BioRegions is the primary platform for partnership between clusters and biocommunities. Members work together to defragment biotechnology in Europe and significantly improve services to support growing clusters and companies. BioTOP was one of the founding members of CEBR in 2004 and is the primary point of contact for Berlin-Brandenburg in Europe. BioTOP contributes significantly to CEBR activities, through its excellent cluster support services and depth of expertise and understanding of company requirements. Through BioTOP, biotechnology within the German Capital Region is visible at a global level; companies and researchers gain maximum benefit from an integrated international network and the opportunities available from clusters across Europe. CEBR is proud to have BioTOP as one of its most active members.




Oliver Rakau
Analyst at Deutsche Bank Research and author of the study "Deutschlands Biotechnologieregionen. Konzentration setzt sich fort" (Germany's Biotechnology Regions. Concentration Continues)

Good Opportunities for Sustained Growth

» When comparing the five leading German biotechnology locations, Munich and Berlin both prove far ahead of the rest as regards a range of criteria. Berlin-Brandenburg is slightly ahead of Munich in terms of the number of companies, but companies in Munich are larger on average and geographically far closer to each other even than in the Berlin region, which facilitates cooperation. On the other hand, Berlin-Brandenburg benefits strongly from having the largest number of research facilities by far. They provide considerable advantages for technology transfer and staff recruitment. The region therefore has excellent preconditions for sustained growth.

Market Segments of Companies



Most companies focus on biomedicine. A total of 85% of companies, focus primarily on development in the areas of new diagnostics, drug development and associated services or technologies. 16% of the companies are active in the agriculture/food sector, white biotechnology/environmental biotechnology amounts to 18% of all entries. (Source: Internal survey, BioTOP database, responses from 200 companies, multiple entries, February 2010)


Biotech Networks

- BioHyTec Network for Biohybrid Technologies
- BioResponse
- Center for Molecular Diagnostics and Bioanalytics (ZMDB)
- DiagnostikNet-BB
- GABI – Genome Analysis in the Plant Biological System
- NetDDD Network for Drug Discovery & Development Berlin-Brandenburg
- Network Glycobiotechnology Berlin-Brandenburg
- Nutrigenomics Network Berlin-Brandenburg
- Regenerative Medicines Initiative Berlin-Brandenburg
- RiNA Network for RNA Technologies
- Ultrastructure Network

Scientific Institutions


- Berlin-Brandenburg Center for Regenerative Therapies
- Berlin Institute of Technology
- Brandenburg University of Technology
- Charité – Universitätsmedizin Berlin
- Fraunhofer Institute for Applied Polymer Research
- Fraunhofer Institute for Biomedical Engineering (IBMT)
- Freie Universität Berlin
- German Heart Institute Berlin
- German Institute of Human Nutrition (DIfE)
- German Rheumatism Research Center (DRFZ)
- Humboldt-Universität zu Berlin
- Institute of Polymer Research of the GKSS Research Centre
- Lausitz University of Applied Sciences
- Leibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB)
- Leibniz-Institut für Molekulare Pharmakologie (FMP)
- Leibniz-Zentrum für Agrarlandschaftsforschung (ZALF) e. V.
- Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch
- Max-Planck-Institute for Colloids and Interfaces
- Max Planck Institute for Infection Biology
- Max Planck Institute for Molecular Genetics
- Max Planck Institute of Molecular Plant Physiology
- Robert Koch Institute
- University of Applied Sciences Berlin
- University of Applied Sciences Wildau
- University of Potsdam

- Bioparks
- Scientific Institutions
- Companies
- Networks



Netzwerk Weite Biotechnologie
Berl-Brandenburg

BIOLINE
CANTERA
CHITACOR





Prof. Dr. Christine Lang
CEO · ORGANOBALANCE GmbH

Bacteria in the Service of Health

» In the ten years since ORGANOBALANCE was founded we have managed to acquire a strong position in white biotechnology based on our expertise in the development of innovative probiotic strains. In 2010, we took another step forward with the founding of ORGANOBALANCE Medical AG. We are convinced that microorganisms can also be developed as effective, safe and well-tolerated products for prevention and therapy in human medicine. Our first major project aims to control the stomach bacterium *helicobacter pylori*. In the Lonza Group, we have found a strong partner for product development and global marketing of an application in food.

Ralf Christoffers

Minister of Economics and European Affairs of Brandenburg

Brandenburg Receives European Region of Excellence Award

» The European Union has awarded the distinction "Region of Excellence" to the state of Brandenburg. I am very pleased by this great honour. After the Committee of the Regions nominated Brandenburg as a 'European Entrepreneurial Region 2011', we received further confirmation that we are right on course in developing Brandenburg as a business location with the award of the European Region of Excellence title. The EU has thereby certified that our state offers companies an environment that stands out in Europe.

EU Commission President José-Manuel Barroso and Minister Ralf Christoffers at the award ceremony honouring Brandenburg as one of three European "Regions of Excellence"



Further deals include the global license agreement closed by the company Organobalance with Lonza for the development and marketing of the unique probiotic agent lactobacillus anti-H-pylori. This probiotic strain is effective against helicobacter pylori. Studies have shown that H-pylori often contribute to the generation of gastric ulcers and gastritis. In April 2010, the biopharmaceutical company Co.don which specialises in cartilage treatments, closed an exclusive agreement with the Swiss company Novomedics to launch the cell-based drug chondrosphere® on the Swiss market. The option to treat damage to cartilage in the knee, hip, elbow and shoulder joints with the three-dimensional autologous cell transplant chondrosphere® provides doctors and patients with new possibilities for gentle and personalised therapy.

Two major transactions were closed in the acquisition sector in 2010. The Berlin service provider for genome research imagenes was taken over to 100 per cent by the British Source BioScience Group. The transaction has created a modern medicine and bioscience service provider unique in Europe offering more than 20 million clones, 90,000 antibodies and a comprehensive range of functional and structural genome analysis services. The company Cyano Biofuels which focuses on biotechnological applications of cyanobacteria and specifically on their development and

optimisation for the production of environment-friendly biofuels and raw chemicals, was fully taken over by the US company Algenol Biofuels.

Further progress was also made in the area of product development. In the drug development segment, companies like NOXXON, Revotar, MOLOGEN and Glycotope launched or already completed their first clinical trials. MOLOGEN initiated Phase II/III approval studies for its colon cancer drug MGN1703. The company is pursuing a promising concept for cancer therapy using the immunomodulator and TLR9 agonist dSLIM, which is based on broad activation of the immune system. Revotar AG completed a major Phase IIa clinical study for COPD (Chronic Obstructive Pulmonary Disease) with positive topline results. Today, around five million people worldwide die of COPD every year, and the numbers are rising.

Overall, the regional industry is developing very well. This positive trend is reflected in the consistent pursuit of development goals by companies in the capital-intensive segments, rising employment, increasing internationalisation and, last but not least, the fact that there have been no insolvencies of importance.

New Biotech Companies

Aevotis GmbH aevotis.com	<p>The core competencies of aevotis lie in the targeted conversion of simple carbohydrate containing substrates (e. g. agricultural by-products, waste streams, inexpensive sugars) to high-value carbohydrate based products, their characterization, processing and testing. Marketable products include novel /optimized enzymes, expression systems, specialized biotransformation and down-stream processes, customized oligomers and polymers for food and non-food uses.</p>
Alacris Theranostics GmbH alacris.de	<p>The company is based on novel translational medicine/systems biology technology developed at the Max Planck Institute for Molecular Genetics in Berlin coupled with preferential access to the world's most cost effective sequencing and genotyping technology. The scientific founders are among the world's foremost experts in sequencing technology, systems biology and bio-medicine. Alacris Theranostics offers its services internationally in Europe and North America.</p>
BG Berlin-Genetics GmbH bg-berlin-genetics.de	<p>BG Berlin-Genetics GmbH is a new provider for genetic diagnostics and consulting in genetic diagnostics. We are a team of experienced human geneticists and have worked for many years in the field of human genetic science and human genetic diagnostics. Our aim is the development of innovative cooperation concepts, to connect classical patient-based medical care centers with modern technology-based service centers. In future, these cooperation forms will enable efficient, high quality, and patient-based genetic diagnostics.</p>
BioSilta Europe GmbH biosilta.com	<p>BioSilta is an international company that specializes in advanced tools for microbial cell cultivation, protein production, enzyme screening and food spoilage testing. The patented EnBase® technology resembles fed-batch mode and provides a cultivation environment with glucose-control, pH maintenance and inhibition of growth-limiting metabolites without the need for traditional mechanical pumps. EnBase® is provided in ready-to-use liquid or tablet products. BioSilta specializes in small-scale cultures and its products offer customer solutions from multi-well plates to small-scale bioreactors.</p>
Botiss medical AG botiss.com	<p>Botiss biomaterials is a privately owned biotech company, headquartered in Berlin. botiss is the leading German specialist for dental bone and tissue regeneration (BTR). We focus on the development of innovative regenerative materials and clinical marketing/distribution in over 50 countries world-wide. The botiss subsidiary Cell+Tissue Bank Austria is a leading European manufacturer of allogenic materials for hard tissue regeneration.</p>
Epinamics GmbH epinamics.com	<p>Epinamics GmbH, a newly established Berlin based pharmaceutical research and development dedicated company, is owner of a proprietary film forming formulation technology platform, the 'Invisible Patch' system. The system is offering a broad basis for the development of formulations for treatment of dermatological diseases as well as for the development of transdermal systems. Currently the development of products has been initiated for the topical treatment of vitiligo and the transdermal treatment of e. g. hypogonadism, climacteric complaints, migraine, emesis. The development of these products and of other active ingredients suitable for this technology will be continued with partners interested in licensing this technology and/or respective products.</p>
Labor Berlin laborberlin.com	<p>The company is the service subsidiary of Europe's largest hospital laboratory for clinical pathology and offers complete solutions for any kind of testing for the ivd industry, CROs, the pharmaceutical industry, life science companies and research facilities. Labor Berlin performs over 20 million analyses in clinical pathology per year; it is the exclusive laboratory partner of Charité – Universitätsmedizin Berlin and the Vivantes Network for Health and provides the diagnostics for approximately 9.000 in-house patients a day and over 800.000 out-patients per year.</p>
ORGANOBALANCE Medical AG organobalancemedical.com	<p>ORGANOBALANCE Medical AG funds and promotes the research and development of novel therapies based on specific probiotic cultures, aiming to develop active substances and mechanisms for innovative medicinal products and medical devices, as well as offer new therapeutic concepts for hitherto inadequately treatable indications.</p>
Pentracor GmbH pentracor.com	<p>In the case of cardiac infarction, C-reactive protein (CRP) results in an increase of the primary damage. Based on a new prototype, the company Pentracor GmbH aims to develop an adsorber for therapeutic reduction of CRP, lead it to approval, establish its certified production and market the product after clinical validation.</p>
RENSA UG renesa.de	<p>Manufacturing and distribution of rapid tests, mainly for medical purposes (Point of Care Testing).</p>
TheraKine BioDelivery GmbH Therakine.com	<p>Development of antibody drug delivery systems and related tasks</p>
UGA Biopharma ugabiopharma.com	<p>UGA Biopharma, a private research and development company, focuses on research, development and commercialization of biopharmaceutical products under contract with other biopharmaceutical companies. UGA Biopharma conducts power of biosciences to develop high-tech, last generation of biomedicine, diagnostic kits, molecular biology items and also offers world class services in biotechnology area.</p>

Surprising Turnaround in VC Financing

The financing situation recovered astonishingly fast in 2010. Following a desolate prior year, there was a marked improvement in industry indicators and in developments in individual companies. The regional biotech companies managed to raise more than 100 million Euros and two new funds for early stage investment have been established.

The industry proved resilient to the financial and economic crisis and weathered the turbulences on the private capital markets well. There are now signs of a capital market recovery, so that the market may be able to meet the continuing high financing needs of the biotechnology and medical engineering industry better than in the prior year.

According to a survey conducted by Fleischhauer, Hoyer & Partner with a panel of 37 leading VC suppliers, investments in Germany increased from 341 million Euros in 2009 to 505 million in 2010 (panellists only). This amounts to a rise by 48% and meant that the pre-crisis level was almost reached again. Most of this capital was invested in the biotech (124 million Euros) and medical engineering (80 million) sectors. In terms of the regional distribution of these investments, Berlin-Brandenburg came in third position after Bavaria and North-Rhine Westphalia. IBB Beteiligungsgesellschaft was again one of the most active investors.

This positive trend was also confirmed by a survey conducted by biotechnologie.de for the year 2010. According to the findings, privately held dedicated biotech companies received a total of 312 million Euros from their investors, which is twice as much as in 2009 (142 million). Listed companies collected a total of 335 million Euros, compared to 122 million in 2009.

According to research by BioTOP, more than 100 million Euros were invested in biotech companies in the Berlin-Brandenburg region in 2010. This is a record compared to the preceding period and higher even than during the pre-crisis year 2008. With app. 60 million Euros, listed companies thereby procured the largest share of investments by capital increases. Among privately held companies, NOXXON AG was the front-runner by a wide margin with investments of 33 million Euros.

Federal Funding (BMBF) for R&D projects in biotech companies

Berlin	14,98
Hamburg	10,04
Baden-Württemberg	7,7
Bremen	7,31
Sachsen-Anhalt	7,03
Thüringen	6,29
Bayern	6,23
Per capita funding (euro), Figures for 2005-2009, source: ConsulTech GmbH, 2010	

In addition to increased private sector investments, the industry also benefited from public-sector funding from the states of Berlin and Brandenburg earmarked for the expansion of the infrastructure and new product developments in the amount of 43 million Euros. In total, some 150 million Euros were therefore invested in the regional industry in 2010. Funding also came from the German federal government and the European Union, which was not examined in detail in our analysis, but is usually in the lower tens of million range.

These very positive results, especially compared to the preceding years, should not obscure three factors, however. First: the majority of the financings mentioned benefited only a small number of companies. It must consequently be presumed that demand for financing remains higher than supply and that many companies sought, but failed to obtain financing. Second: Start-up financing is more or less non-existent. This is reflected not only in the number and quality of start-ups, but also in the difficulties experienced by enterprises which received pre-seed financing, e.g. from the federal programmes Go-BIO or EXIST, but now have major problems finding start-up financing despite having reached an advanced development stage over the years. The High Tech Gründerfonds (HTGF) has certainly been the most successful instrument for financing technology-focused start-ups for many years. But not every start-up matches the requirement profile of the HTGF, so that many founders have to look elsewhere for

Dr. Joachim Rautter

Managing Director
Peppermint Venture Partners GmbH



financing. Third: Apart from the validation support programme VIP of the German Federal Ministry of Education and Research (BMBF), there is no effective instrument for translating the innovation potentials in academic research at universities into commercial applications. It is therefore to be hoped that VIP will be continued and improved in certain respects to become even more effective.

New pre-seed and start-up funds have been established in Berlin-Brandenburg which is to create new dynamism in certain areas. Investitionsbank Berlin has set up the Technology Development Fund TEF which is to support the development and marketing of inventions at the Berlin universities. The aim is to overcome the present barriers to utilisation and continued development by a clear marketing-oriented focus. The inventions at Berlin's universities are managed and supported by ipal GmbH which also proposes projects suited for the IBB's TEF programme. In the start-up segment, Peppermint has initiated a second venture fund together with Stiftung Charité: the Charité Biomedical Fund. The Charité Biomedical Fund is an independent fund that invests in young companies in the health sector which have a first proof of concept. The fund focuses on companies in the medical engineering and health services segments, whereby the pharmaceutical segment is also considered selectively.

New Fund for Startups in Biomedicine

» The Charité Biomedical Fund, which was launched by Peppermint Venture Partners GmbH in November 2010, provides young companies in the region with a new private partner for venture capital financing. With a volume of currently 25 million Euros, the fund is planning to invest in ten to fifteen companies. Investments will focus on medical devices, but medical services and the biotechnology sector will also be considered. The viability of the technology or the business model (proof of concept) is a key investment criterion. The new fund is cooperating closely with Charité under a cooperation agreement, so that potential spin-offs from the Charité and the research facilities cooperating with it will be one of the focus areas of Charité Biomedical Fund investments.

Funding for the Market Launch of Medical Products for the Isolation of Rare Cells from Blood

» In addition to our technology as a key differentiator, a further strength of GILUPI is our good investor team. It makes me very proud that, in addition to the ERP Start Fund at KfW Mittelstandsbank, all of our existing investors are contributing to the follow-up financing with more than 3.6 million Euros and thereby supporting our growth strategy. This financing round will not only enable us to bring to market our first product, the Nanodetector Cancer01, but also to create the structure required for future cooperation ventures.

Klaus Lücke

Founder and Managing Director
of GILUPI GmbH



The BioCampus Network Berlin-Brandenburg

Berlin-Brandenburg boasts six biotechnology parks, which offer optimal space for the specific requirements of every company. This geographic concentration of specific biotech parks is unique in Germany and probably in all of Europe. The parks differ in their offers and strategic focus and provide ideal conditions for newcomers. More than half of the 200 companies are currently utilizing the infrastructure of a publicly or privately managed park. In addition, the young companies benefit from the closeness to science and the permanent contact and exchange.

Campus Berlin-Buch

Interaction of Research, Clinics and Companies

Berlin-Buch is the location of one of the largest biotechnology parks in Germany, with 26.000 square meters of scalable lab and office space for start-ups and maturing companies. Situated to the northeast of the city, the Berlin-Buch Campus is currently home to 49 companies, 35 of which are biotech companies; the rest provides support services.

Beside the BiotechPark the Max Delbrück Center for Molecular Medicine, the Leibniz Institute for Molecular Pharmacology as well as clinical groups from the Charité University Hospital within the Experimental and Clinical Research Center are part of the Campus community. The Campus gives access to high-end technology platforms, state of the art infrastructure, interdisciplinary communication, projects and expertise in a wide range of items, especially in translational research.

The BiotechPark at the Campus Berlin-Buch offers:

- Immediately available lab and office space
- Excellent research and clinical expertise on-site
- Training programs for personnel on spot
- An international community of like-minded people
- Interdisciplinary networks and platforms

The BiotechPark including the Innovation and Incubation Center is managed by BBB Management GmbH Campus Berlin-Buch. Acting as a full-service company BBB's main tasks are the settlement, accompanying and support of Biotech businesses.

Biotechnology Park Luckenwalde

Space for Expansion

Located just 25 miles from the new Berlin-Brandenburg International Airport (BBI) in the rural district of Teltow-Flaeming, the Biotechnology Park Luckenwalde is one of the most modern facilities of its kind in Germany. It is home to 38 companies with 500 employees from Germany, USA, UK, Korea, India, Italy and Russia.

Companies in the park focus on the development and production of pharmaceuticals, recombinant proteins and diagnostic kits, biological/chemical substances for biotech and pharmaceutical applications, as well as fine chemicals. There are also suppliers of medical technology, analytical services, and a Biotech Education Centre. Technical Equipment comprises completely furnished S2 laboratories (safety workbench, autoclave, dishwasher, deionized water, water purification system, central media supply (compressed air, N₂, CO₂, O₂, H₂), storage and cool rooms, pharmaceutical clean rooms category (B/C), 400 MHz NMR spectrometer, meeting rooms, conference hall (300 seats), library, restaurant with catering service. The entire central technique meets GMP/ISO 9001 specifications.

The park management offers comprehensive, individual services and advice during the settlement and development of firms, including support for the implementation of quality management systems and GMP certification. Currently the park offers 15.000 sq.m. labs and office space, and additional 100.000 sq.m. industrial property ready for expansion.





Berlin Adlershof

The "City of Science, Technology and Media"

Berlin Adlershof is one of the most successful high-tech locations in Germany with focus on photonics and optical technologies, material and microsystems technology, information and media technology, as well as biological, environmental and energy technology.

There are currently 25 biotech companies in Adlershof occupying 18,200 sq.m of lab and office space. The environmental, biological and energy technology companies focus on:

- **Analysis**

Tracing substances in foodstuffs and groundwater, cosmetics, waste; Quality assurance, Identification of pollutants

- **Biotechnology**

Research development and marketing or manufacture of base materials for biotechnology and chemical processes, of bio-chips and biochip-based biomedical procedures, of technical enzyme preparations

- **Environmental technology**

Remediation work based on innovative microbiological processes for degradation of pollutants or production of specific microbial anaerobes; Research in the field of supercritical media and high-pressure technology; High-sensitivity detection systems for biotechnology and genetic engineering; Laser technology

- **Pharmacy, Medicine and Medical Technology**

Equipment engineering and measurement technology; Research for medical chemistry

Technical Equipment comprises laboratories with a basic equipment: security-lockers, laboratory basins, work benches, vacuum supply, preliminary setup for supply of pure gases and compressed air, reconfiguration for further media and gases, central cooling, preliminary setup for cold water supply in rental areas, refitting of heat exchanger by the tenant possible.

BIOTECH CAMPUS POTSDAM

Research on the Waterfront

Just a few minutes away from Potsdam's central railway station in the direction of Caputh, BIOTECH CAMPUS POTSDAM is located on the Hermannswerder peninsula in the river Havel. It is owned and operated by BIOTECH CAMPUS POTSDAM GmbH, a fully owned subsidiary of the Investment Bank of the State of Brandenburg.

The biotechnology centre is housed in four buildings dating from around 1900 and one modern complex and offers a total of 11,400 square meters of laboratory, office, greenhouse and storage space. With such a large facility at its disposal, it offers biotechnology companies an ideal environment for successful operations. All labs are approved as S1 laboratories and meet the building requirements for approval as S2 labs.

The Hermannswerder site also includes an S3 laboratory as a special resource. The beautiful, park-like setting of the peninsula offers an excellent environment for research activities. The island hotel and a conference centre are located directly next to the campus. The site also includes a self-service restaurant and small island shop.

The philosophy of BIOTECH CAMPUS POTSDAM was, and still is, to create the freedom for research and innovation in the high-tech sector of biotechnology. Reputable firms from the industry can indeed be found here. The work carried out by resident companies is multi-faceted, ranging from green biotechnology, the development of vaccines, the development of pharmacologically active substances based on plant materials, the development and production of PCR tests for food testing and preclinical contract research right through to medical technology. A total of 200 employees work on the site.



berlinbiotechpark

In the very heart of Berlin

berlinbiotechpark is located on a 86,000 m² site in the very heart of Berlin, currently offering a total of approx. 57,000 m² of office, laboratory and production space, with a building potential for another 45,000 m² of rental area.

The site, which is home to 32 Biotech/Pharma/Service Companies is supplied with a complete range of media for laboratory and production purposes, with production steam with possibility to upgrade to HP steam, power supply, compressed-air, nitrogen and other inert gases, cooling water, DI-water, with possibility to upgrade to aqua purificata and water for injection, all being provided at favorable rates. The infrastructure includes a canteen and conference facilities as well as works security and waste disposal services. It is rounded off by production-related services such as plant engineers and laboratory technicians, industrial safety engineers, a medical service as well as best-buy services and communication services.

Offering flexible growth potential, production-orientated media equipment and comprehensive industrial-specific services and infrastructure, berlinbiotechpark is particularly attractive for growing internationally orientated technology companies. Furthermore, it offers a permanent base in Berlin for developing companies that have outgrown the size allowed by their limited start-up funding. The inner-city location and the excellent public transport guarantee short ways to all scientific institutions and hospitals of the city.



Science Park Potsdam-Golm

Connecting Excellence

Science Park Potsdam-Golm combines cutting-edge international research and the training of young scientists in a high-powered location in the immediate vicinity of the German capital Berlin. Alongside the Faculty of Science and the Human Sciences Faculty of the University of Potsdam, three Institutes of the Max Planck and two of the Fraunhofer Society as well as an innovation center with currently 18 companies operate in Brandenburg's largest science park.

More than 2500 people work at Potsdam-Golm and more than 7500 students are pursuing their academic qualifications here. The pleasant and very family-friendly working environment on the edge of a nature conservation area, the high quality of life in and around Potsdam and continuous growth make Potsdam-Golm a highly attractive location. Professional site management is extending the park infrastructure and fosters the integration of the capabilities and interests of all institutions, associations and companies that operate at Science Park Potsdam-Golm.

The GO:IN Innovation Center offers young technology-based companies and entrepreneurs a range of office and laboratory spaces along with extensive services and optimal support for a successful market launch. Close proximity to the other players at Potsdam-Golm and the intensive networking of the different institutions and companies here offer perfect conditions for the development and exploitation of synergies.





Co:bios Technologiezentrum

The co:bios Technology Center in Hennigsdorf was established in 1998 under the name of Biotech GmbH, with the aim to promote the structural transformation of the economic region of Berlin-Brandenburg, to one of today's most advanced life science centers in Germany. More than 10 years after its founding Hennigsdorf is now a magnet for the healthcare industry.

We offer affordable rental opportunities and a selected portfolio of services and advice to young start-ups as well as medium-sized companies. Therefore Hennigsdorf is a center of excellence for life sciences, especially in the field of red biotechnology and medical technology.

In close cooperation with the State of Brandenburg and the surrounding public and private research institutions, we support young companies across all stages of growth. With our holistic approach combining settlement, development, construction and licensing issues to the point of traditional management consulting, we successfully gave home to more than 20 companies providing a total of about 500 jobs.



Addresses

Campus Berlin-Buch

Robert-Rössle-Straße 10 · 13125 Berlin
 Phone +49 30 94892511 · Fax +49 30 94893812
 info@bbb-berlin.de · www.bbb-berlin.de
 Contact: Dr. Andreas Mätzold · Executive Manager
 Dr. Ulrich Scheller · Executive Manager

Biotechnologiepark Luckenwalde

c/o SWFG mbH
 Im Biotechnologiepark, TGZ I · 14943 Luckenwalde
 Phone +49 3371 681100 · Fax +49 3371 681105
 bio-luck@swfg.de · www.bio-luck.de
 Contact: Dipl.-Ing. Christoph Weber · Director

Adlershof Zentren für Biotechnologie und Umwelt

WISTA-MANAGEMENT GMBH
 Rudower Chaussee 17 · 12489 Berlin
 Phone +49 30 63922221 · Fax +49 30 63922212
 terytze@wista.de · www.adlershof.de
 Contact: Heidrun Terytze · Head of Center for Biotechnology and Environment

BIOTECH CAMPUS POTSDAM

Steinstraße 104-106 · 14480 Potsdam
 Phone +49 331 6601699 · Fax +49 331 6601628
 info@biotechcampus.de · www.biotechcampus.de
 Contact: Gabriele Ziegler

berlinbiotechpark

Tegeler Weg 33 · Max-Dohrn-Straße 8-10 · 10589 Berlin
 Phone +49 30 20364205 · Fax +49 30 20364190
 info@berlinbiotechpark.de · www.berlinbiotechpark.de
 Contact: Ingo Schneemann

Standortmanagement Golm gGmbH

GO:IN Golm Innovationszentrum GmbH

Am Mühlenberg 11 · 14476 Potsdam-Golm
 Phone +49 331 237351130
 www.wissenschaftspark-potsdam.de · www.goin-potsdam.de
 Contact: Friedrich W. Winskowski · Managing Director

Co:bios Technologiezentrum

Neuendorfstraße 20 a · 16761 Hennigsdorf
 Phone +49 3302 2021250 · Fax +49 3302 2021257
 info@cobios-technologiezentrum.de
 www.cobios-technologiezentrum.de

From Basics to Very Special Things

One big plus of Berlin-Brandenburg as a biotech region is its very broad range of education programmes in the life sciences. It extends from nursery schools to postgraduate colleges and specialised further education programmes in the regulatory field. On our website, BioTOP provides extensive information about the available degree courses and further education events in the region.



Since spring 2008, BioTOP Berlin-Brandenburg arranges "BB LIFE" – events which provide information on a wide range of regulatory themes. To date, the "BB LIFE" team has welcomed more than 1,500 participants to these events.

BB LIFE is designed for SME in the sectors pharmaceuticals, biotechnology, medical products/medical engineering and in vitro diagnostics. The seminars provide extensive information about the preconditions and recommended procedures for the development, testing, manufacturing, approval and marketing of products and for the provision of services for these product groups. In addition to some "classics", new themes are continuously researched based on the information needs of participants to ensure that all current developments in the regulatory field are addressed optimally. In the seminars participants heard talks from 215 speakers to date, the majority of whom work in regional companies and research establishments.



The "SchülerBIONNALE" is a real runner. In 2010 it had 600 participants, and in 2011 some 1400 school students have already completed the programme and explored the many career options in the biosciences.

Comprehensive training programs

Berlin-Brandenburg offers an extremely broad range of academic programmes of study. The guide "Studium Gesundheit in Berlin und Brandenburg" compiled by the cluster presents around 140 different health-related course programmes at the universities. And our training atlas presents more than 60 health sector professions for which people can train in the region.

See: www.atlas-studium.de and www.atlas-ausbildung.de





Dr. Ralf Schweitzer
Project Manager
BB LIFE



Since September 2010, Berlin has a new attraction: the "Humboldt Bayer Mobil". It provides science on wheels: A 14 metre truck converted into a mobile science laboratory offers school students the option of experimenting and conducting research like real scientists outside the classroom. The project is the result of a joint initiative of Humboldt-Universität zu Berlin and the Bayer Science & Education Foundation as well as Stiftung Humboldt-Universität.

High need for further education on regulatory themes

» The excellent response has shown that our selection of topics and our highly qualified speakers meet the needs of our audience very well. Detailed knowledge of the regulatory environment and of the options for implementing regulatory requirements in practice is of central importance to entrepreneurial success and to the sustainability of newly founded companies as well as companies that locate in the region.

The "Humboldt Bayer Mobil" visits around 20 primary and secondary schools in Berlin and Brandenburg every year. School students between the ages of eleven and 15 can acquire hands-on experience of the sciences at 15 different workstations inside the truck. For example, they may measure their physical endurance with an ECG, analyse the environmental conditions in their neighbourhood, plan a polar expedition, analyse fingerprints or engage in a wide range of other exciting scientific endeavours. The "Humboldt Bayer Mobil" is equipped with state-of-the-art research equipment and measuring devices that make all this possible.



Excellent Corporate Locating and Project Development Services

Berlin-Brandenburg is Germany's leading life science center and one of Europe's main health industry locations. Due to its high concentration of science and research establishments, the region offers outstanding potentials for technological development and cooperation. The joint Life Science Team of the economic promotion agency Berlin Partner and the Brandenburg Economic Development Board (ZAB) supports the life science industry with a full range of services, including marketing activities at national and international exhibitions.



Carolin Clement
Head of Business Unit Life Sciences
Berlin Partner GmbH



Dr. Ute Hartmann
Head of Business Unit Life Sciences
Brandenburg Economic Development Board



The Berlin-Brandenburg Night, hosted by Bayer HealthCare, is one of the attractions around the annual BIO International Convention. In 2011 it will take place on June 27th, 9 pm, at Washington DC's famed W Hotel terrace.

The Life Science Screening Package Berlin-Brandenburg is tailored to the needs of the biotech sector. This program supports companies looking for cooperation partners, networks, service providers and research institutions. All segments of the health industry are present in the region. The high concentration of international excellence facilitates interdisciplinary exchange and makes new landmark developments easier to achieve – this is what makes Berlin-Brandenburg so interesting and attractive for the life sciences. At the same time, however, the sheer number of players can make it difficult to find the right partner. Our staff and the colleagues at BioTOP have been in direct contact with virtually all companies and scientific institutions in the region for many years and can therefore provide immediate access to the right contacts.

The other services of Berlin Partner include the Business Welcome, Business Financing, Business Locating and Business Recruiting Package. They help our clients test Berlin as a location, procure support and funding and identify suitable commercial real estate or professional staff. The Business Location Center (BLC) presents all relevant economic data and a 3D model online and in its showroom. Its comprehensive information service covers sector data, regional information, area maps, geographic data, the available funding programs, a commercial real estate database as well as labor market and infrastructure data. A new offer was launched last year: the Investor Services. This service supports companies in the region in all aspects of corporate expansion and strategy in cooperation with the Berlin Senate Administration for Economic

Development, Technology and Women, the twelve Berlin precincts and other service partners.

The performance range of the one-stop agency ZAB includes corporate strategy, innovation, technology and foreign trade services, support for technology transfer and for the establishment of corporate networks. Under its „Big Directive“, the state of Brandenburg now also sponsors innovative cooperation projects between research institutes and companies. Here, landmark initiatives include the Tele-Diagnostics cooperation project (with funding of app €10 million) and TERA-Sens (€15 million). The participating partners include the Fraunhofer Institute for Biomedical Engineering, the University of Potsdam, the Leibniz Institute for Innovative Microelectronics (IHP) and the companies B.R.A.H.M.S AG (Thermo Fisher Scientific), MEYTEC GmbH and LIMETEC Biotechnologies GmbH.

In 2010 the Life Science Team supported expansion projects and provided locating services to 28 companies, including Pfizer Deutschland GmbH which is transferring further divisions to Berlin with some 200 new jobs, and mdc GmbH which opened a subsidiary in Berlin-Adlershof.

Here for you. For your health.

Medical knowledge is our fascination. Together with our associates in research, science and education we help millions of people all over the world. We are obliged by our medical improvement, because health matters!



AVS 903 10 022

www.sanofi-aventis.com

sanofi aventis
Because health matters

UHY Deutschland AG
Wirtschaftsprüfungsgesellschaft

Berlin / Bremen / Cologne / Frankfurt / Hamburg / Munich

Life sciences companies are in safe hands with UHY.

UHY Deutschland AG is a joint venture of long established medium-sized auditing and consulting firms with a total of 140 employees and partners.

As a member of UHY International, a global association of independent accounting and consulting firms with about 6,300 employees we can provide audit, accounting, tax and consulting services in 235 business centres across the globe.



UHY Deutschland AG has extensive experience in financial and consulting services for life sciences companies for many years. We offer the following services:

- Audits of financial and consolidated statements under the German Commercial Code (HGB) and IFRS
- Accounting & Reporting
- Due diligence (financial and tax) and business valuations
- Consulting services on IPOs
- Business Advisory
- Mergers & Acquisitions (M&A)
- German and international taxation

Contact

Dr. Ulla Peters or Reinhold Lauer

UHY Deutschland AG Wirtschaftsprüfungsgesellschaft / Zimmerstraße 23 / D-10969 Berlin
Phone +49 30 226593-0 / Fax +49 30 22679050 / www.uhy-deutschland.de / www.uhy.com



HealthCapital
BERLIN BRANDENBURG

Healthcare Industry Network Berlin Brandenburg

**Encompassing all healthcare activities
in Berlin and Brandenburg**

Linking partners in research, hospitals,
clinics, business and industry

Promoting and enabling cross-sector
medical innovations

www.healthcapital.de



Senatsverwaltung für Wirtschaft,
Technologie und Frauen

This project of the TSB Innovationsagentur Berlin GmbH is subsidized by the Investitionsbank Berlin, with funding provided by the Berlin Senate Department for Economics, Technology and Women.



Addresses 2011 BioTOP-Report

Networks	48
Biotech Parks	49
IP Asset Management	49
Universities and Research Centers	49
Banks and VCs	50
Supporting Organisations	51
Pharmaceutical Companies	51
Contract Manufacturers	52
Contract Research Organisations	52
Biotech Companies	53

Networks		
BioHyTec – Verein für Bioanalytik und Biohybrid-Technologien e.V.	BioHyTec is the biohybrid technology network in the life sciences cluster of Berlin-Brandenburg. This new field of technology is the interface between biosensor development and microsystems technology. Biohybrid systems open up new applications in pharmaceutical research, clinical diagnostics, food analysis and genetic engineering.	biohytec.de
BioResponseNetzwerk	BioResponse is an interdisciplinary research and development organisation with members from Brandenburg, Berlin and Saxony. It focuses on the development and marketing of multiplex assays for diagnostic antibody identification based on the proprietary BioResponse technology, which is comprised of fully automated image analysis of fluorescence-encoded microparticles and labelled cell structures.	bioresponse.de
DiagnostikNet-BB Netzwerk Diagnostik Berlin-Brandenburg	DiagnostikNet-BB is the Berlin-Brandenburg network for in vitro diagnostics. Members include biotech companies as well research institutes and clinics. Main objectives of the network are: Development of system solutions, optimizing compatibility, close cooperation with leading clinicians and joint marketing.	diagnostiknet-bb.de
GABI – Genomanalyse im Biologischen System Pflanze	GABI stands for Genome Analysis of the Plant Biological System and is an associative project supported by the German Federal Ministry of Education, Research and Technology (BMBF) as well as a number private enterprise companies. These companies are grouped under the Business Platform promoting Plant Genome Research GABI e.V. (WPG). A Patent and Licence Agency associated with GABI (GVS) has the task of commercialising and protecting research results by means of licence rights.	gabi.de
Glykostrukturfabrik	The Network Glycobiotechnology Berlin-Brandenburg brings together scientists with many different areas of competence in studying and utilizing complex carbohydrates. The aim is product-oriented development of the region's wide range of glycobiological technologies, building a complete glyco-technological process chain and to establish the region as a center of competence in the field of glycobiotechnology.	glykostrukturfabrik.de
Health Capital Berlin-Brandenburg	In order to develop the scientific and economic position of the region, the governments of the states of Berlin and Brandenburg have put the master plan "Healthregion Berlin Brandenburg" into effect. Its key to a continued success is a continued close interplay between research, development and education / vocational training with production, application and supply. All of these activities are integrated and coordinated through the Network "Gesundheitswirtschaft Berlin Brandenburg" under the brand of "HealthCapital".	healthcapital.de
Net-DDD Network for Drug Discovery & Development Berlin-Brandenburg	The Network for Drug Discovery & Development Berlin-Brandenburg was launched in 2007 as an open interdisciplinary initiative with the aim to accelerate the transfer of clinical relevant findings into innovative drugs and therapeutic concepts. The network, which was co-founded by the Leibniz Institut für Molekulare Pharmakologie (FMP) and the competence network biotechnology, BioTOP Berlin-Brandenburg, offers state-of-the-art technology and expertise in the field of drug discovery.	drugdiscoverynet.de
Netzwerk Nutrigenomik Berlin-Brandenburg	Nutrigenomics is a highly innovative and fast-growing interdisciplinary field of research linking genome research, plant biotechnology and molecular nutritional research and offering new applications for medicine and nutrition. Nutrigenomics aims at providing an understanding for how nutrition affects the balance between health and disease. Network partners include local universities and research institutes, private enterprises, public-sector organizations and various collaborative project groups.	nutrigenomik.de
Netzwerk Weiße Biotechnologie Berlin-Brandenburg	The White Biotechnology Network serves as an engine for the advancement of the white biotechnology in the Berlin-Brandenburg region. By combining of a number of competencies, the partners in the network are capable of developing innovative solutions for complex problems in den fields of chemistry, paper, cosmetics, pharmaceuticals and food.	weisse-biotechnologie-bb.de
Regenerative Medicine Initiative Berlin-Brandenburg	The mission of the RMIB is to promote the Berlin-Brandenburg region as a center of excellence for Regenerative Medicine particularly for cell-based medical biotechnology. The RMIB promotes networking in the field and supports the further development of clinical studies and education programs. The initiative fosters the collaboration between universities, research institutes, companies (including SMEs) and organizations in the field of science and technology.	rmib.de
RiNA – Netzwerk RNA-Technologien	The RNA-Network provides ongoing support and funding for the development of RNA technologies with the goal to commercialize the results. One main focus is the improvement and application of the RNA interference technology. Further projects develop RNA aptamers, cell-free protein biosynthesis systems and analyse the structure and function of RNA molecules. The RiNA RNA-Network encourages co-operation and information exchange between academy and industry.	rna-network.com
Ultrastrukturnetzwerk	The Ultra Structure Network brings together researchers in the field of structural proteomics with the aim of conducting high-throughput analysis of supramolecular structures using mass spectrometry (MS) and cryoelectron microscopy.	ultrastrukturnetzwerk.de
Zentrum für Molekulare Diagnostik und Bioanalytik	The Centre for Molecular Diagnostics and Bioanalytics (ZMDB) is a virtual centre operated under the auspices of the Fraunhofer Institute for Biomedical Technology and the Charité – Universitätsmedizin Berlin in close cooperation with the region's company networks. The aim is to bring together regional expertise in basic research, technology development, clinical research and industrial cooperation initiatives to set up joint projects that will speed up the development of in vitro diagnostics "Made in Berlin-Brandenburg".	zmdb.de

Biotech Parks		
berlinbiotechpark	berlinbiotechpark is located on a 86,000 m ² site in the very heart of Berlin, currently offering a total of approx. 57,000 m ² of office, laboratory and production space, with a building potential for another 45,000 m ² of rental area. Offering flexible growth potential, production-orientated media equipment and comprehensive industrial-specific services and infrastructure, berlinbiotechpark is particularly attractive for growing internationally orientated technology companies.	berlinbiotechpark.de
Biotech Campus Potsdam	Just a few minutes away from Potsdam's central railway station in the direction of Caputh, BIOTECH CAMPUS POTSDAM is located on the Hermannswerder peninsula in the river Havel. It is owned and operated by BIOTECH CAMPUS POTSDAM GmbH, a fully owned subsidiary of the Investment Bank of the State of Brandenburg.	biotechcampus.de
Biotechnologiepark Luckenwalde	Located just 30 miles south of Berlin and 25 miles from Berlin-Brandenburg International Airport in the rural district of Teltow-Flaeming, the Biotechnology Park Luckenwalde is one of the most modern facilities of its kind in Germany. It is home to 38 companies with 500 employees from Germany, USA, UK, Korea, India, Italy and Russia.	bio-luck.de
Co:bios Technologiezentrum GmbH	The co:bios Technology Center in Hennigsdorf offers affordable rental opportunities and a selected portfolio of services and advice to young start-ups as well as medium-sized companies. Therefore Hennigsdorf is a center of excellence for life sciences, especially in the field of red biotechnology and medical technology.	cobios-technologiezentrum.de
Campus Berlin-Buch bbb Management GmbH	Berlin-Buch is home to one of the largest biotechnology parks in Germany, with 26.000 square meters of scalable lab and office space for start-ups and maturing companies. Situated to the northeast of the city, the campus is currently home to 49 companies, 35 of which are biotech companies; the rest provide support services.	bbb-berlin.de
Adlershof Zentren für Biotechnologie und Umwelt	Berlin Adlershof is one of the most successful high-tech locations in Germany with focus on Photonics and optical technologies, material and microsystems technology, information and media technology, biological, environmental and energy technology. There are currently 25 biotech companies in Adlershof occupying 18,200 sq.m of lab and office space.	adlershof.de

Other Parks		
Science Park Potsdam-Golm GO:IN Golm Innovationszentrum GmbH	Science Park Potsdam-Golm is one of the most innovative and promising locations in Brandenburg. In the GO:IN facility, innovative companies will find an excellent working environment where they will benefit from the synergy effects of the location and the specific equipment offered by its laboratories. The location provides a wide range of services and consulting, as well as integration into the existing regional networks.	wissenschaftspark-potsdam.de goin-potsdam.de
Innovationspark Wuhlheide Managementgesellschaft mbH	On the 80,000 acre Technology Campus Innovation Park Wuhlheide, small and medium-sized companies will find perfect conditions to pursue their ideas and business goals. The companies working on the Campus come from a variety of disciplines and sectors and are mainly technology-oriented.	ipw-berlin.de

IP Asset Management		
Ascenion	Ascenion advises public life science research institutions, universities, hospitals, freelance inventors and companies in all aspects of intellectual property asset management.	ascenion.de
ipal GmbH intellectual property asset management	ipal assesses and markets the inventions of Berlins university scientists and academics on an exclusive basis and is financed by the Berlin universities as well as the Investment Bank Berlin (IBB). Cooperation agreements exist with Charité, RKI, PEI, BAM and other excellent research institutes.	ipal.de
ZukunftsAgentur Brandenburg GmbH Brainshell	Brainshell is an independent consulting agency specializing in intellectual property services for businesses. Brainshell manages and markets the patent portfolios of all colleges, universities, and research institutes in the State of Brandenburg.	brainshell.de

Universities and Research Centers		
BAM Federal Institute for Materials Research and Testing		bam.de
Berlin-Brandenburg Center for Regenerative Therapies		b-crt.de
Berlin Institute of Technology		tu-berlin.de
BfR Federale Institute for Risk Assessment		bfr.bund.de
Brandenburg University of Technology		tu-cottbus.de
Charité – Universitätsmedizin Berlin		charite.de
Deutsches Rheuma-Forschungszentrum Berlin		drfz.de

Universities and Research Centers

Fraunhofer Institute for Applied Polymer Research (IAP)	iap.fhg.de
Fraunhofer Institute for Biomedical Engineering (IBMT)	ibmt.fraunhofer.de
Freie Universität Berlin	fu-berlin.de
German Heart Institute Berlin	dhzb.de
German Institute of Human Nutrition (DIFE)	dife.de
Humboldt-Universität zu Berlin	hu-berlin.de
htw Berlin – University of Applied Sciences	htw-berlin.de
Institute of Polymer Research of the GKSS Research Centre	gkss.de
Institute for the Reproduction of Farm Animals Schönnow Inc.	ifn-schoenow.de
Lausitz University of Applied Sciences	fh-lausitz.de
Leibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB)	atb-potsdam.de
Leibniz-Institut für Molekulare Pharmakologie (FMP)	fmp-berlin.de
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch	mdc-berlin.de
Max Planck Institute for Infection Biology	mpiib-berlin.mpg.de
Max Planck Institute for Colloids and Interfaces	mpikg-golm.mpg.de
Max Planck Institute for Molecular Genetics	molgen.mpg.de
Max Planck Institute of Molecular Plant Physiology	mpimp-golm.mpg.de
Robert Koch Institute (RKI)	rki.de
University of Applied Sciences Berlin	beuthhochschule.de
University of Applied Sciences Wildau	th-wildau.de
University of Potsdam	uni-potsdam.de

Banks and VCs

BC Brandenburg Capital GmbH	bc-capital.de
Berliner Sparkasse-Kompetenzzentrum Gründungen und Unternehmensnachfolge	lbb.de
Berliner Volksbank eG	berliner-volksbank.de
bmp Life Science AG	bmp.com
Business Angels Club Berlin e.V.	business-angels-berlin.de
CCM Columbus Capital Management	columbusco.com
Commerzbank AG	commerzbank.com
Creathor Venture	creathor.de
Deutsche Bank AG	db.com
High-Tech Gründerfonds Management GmbH	high-tech-gruenderfonds.de
IBB Beteiligungsgesellschaft mbH	ibb-bet.de
Investitionsbank Berlin	ibb.de
Investitionsbank des Landes Brandenburg	ilb.de
KfW-Mittelstandsbank	kfw-mittelstandsbank.de
Peppermint Financial Partners GmbH	PEPPERMINT-vc.de
Triginta Capital	triginta-capital.com/life-science.htm

Supporting Organisations		
Berlin Partner GmbH	Support of international and domestic companies in all issues regarding locating to Berlin	berlin-partner.de
BioTOP Berlin-Brandenburg	BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning biotechnology in the German capital region.	biotop.de
Investitionsbank Berlin (IBB)	Company financing and consultation on subsidies and processing grant applications in Berlin.	ibb.de
Investitionsbank des Landes Brandenburg	Company financing and consultation on subsidies and processing grant applications in Brandenburg.	ilb.de
Landesamt für Gesundheit und Soziales Berlin (LAGeSo)	One Stop Agency for all licensing and approvals, for questions concerning biomedicine, biotechnology and pharmaceuticals and for more general issues connected with health, disease control and public health in Berlin	berlin.lageso.de
TCC Technologie Coaching Center	Specific Coaching offers for innovative high tech companies	tcc-berlin.de
Technologie Stiftung Brandenburg	The technology Foundation Brandenburg is dedicated to the advancement of science and research, especially in the field of innovative technologies.	ts-bb.de
TSB Technologiestiftung Berlin Gruppe	The TSB Technology Foundation Berlin Group is a public private partnership in the German capital region to develop science and industry networks for technology transfer, joint projects, and regional innovation strategies.	tsb-berlin.de
TSB Innovationsagentur Berlin GmbH	The TSB Innovation agency supports small and medium-sized companies in the management of innovation processes.	tsb-berlin.de
ZAB Zukunftsagentur Brandenburg	The Brandenburg Economic Development Board functions as a one-stop agency for all kinds of business support services.	zab-brandenburg.de
ZAK Zentrale Anlauf- und Koordinierungsstelle Senatsverwaltung für Wirtschaft, Arbeit und Frauen	Helps you find your way through the Berlin administration. Supports complex urban development policy and investment projects.	berlin.de/sen/wirtschaft/zak/wir

Pharmaceutical Companies		
Bausch & Lomb Dr Mann Pharma	Bausch & Lomb is the eye health company dedicated to perfecting vision and enhancing life for consumers around the world. Core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products.	bausch-lomb.de
Bayer HealthCare Pharmaceuticals	Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG. The company markets its products in more than 100 countries, and in 2010 generated sales of almost € 11 billion. More than 38,000 members of staff currently work for Bayer HealthCare Pharmaceuticals worldwide – more than 6,200 in research and development alone.	bayerpharma.com
BERLIN-CHEMIE Aktiengesellschaft	BERLIN-CHEMIE is a German subsidiary of the MENARINI Group. The company, which was formed in 1886 and is headquartered in Florence, was developed over the generations to become a global, owner-managed pharmaceutical company. Research is centred on the development of innovative drugs for the following areas: inflammatory diseases and pain, cardiovascular diseases, oncology, viral disease.	berlin-chemie.de
CT Arzneimittel GmbH	CT Arzneimittel is a pharmaceuticals company that focuses on generics production. Prescription medicines form the bulk of the product portfolio, which includes some 1,200 drugs with more than 200 different active agents that are used to treat the most common clinical syndromes.	ct-arzneimittel.de
Dr. Kade Pharmazeutische Fabrik GmbH	The company's activities concentrate on the production and marketing of drugs in the fields of gynecology, proctology, pain relief/ rheumatism and urology. The potential of proven drugs is expanded systematically by galenic developments to produce innovative products.	kade.de
Heyl chemisch pharmazeutische Fabrik GmbH & Co. KG	HEYL is an independent, entrepreneurial family business that has its headquarters in Berlin, since its establishment in 1926. In cooperation with its international subsidiaries, the main focuses of the work are the Regulatory Affairs and marketing of medicines as well as the sale of active pharmaceutical ingredients (API's) and special chemicals.	hey1-berlin.de
Intendis GmbH	Intendis is a specialized pharmaceutical company focused on the Dermatologicals category. Headquartered in Berlin, Germany the company was founded in 2005 as a subsidiary of Schering AG. Intendis has a successful track record of providing prescription drug products for the treatment of severe skin diseases and was a pioneer in the development of locally applicable corticosteroid treatments.	intendis.com
Klosterfrau Berlin GmbH	For more than 175 years Klosterfrau has been developing, manufacturing and marketing pharmaceutical products. The profile of traditional yet modern natural medicines has grown significantly in recent times. Based on the latest scientific discoveries combined with the development of new markets, the range is constantly being expanded with innovative products.	klosterfrau.de
medphano Arzneimittel GmbH	medphano Arzneimittel in Rüdersdorf stands for proven and cost-effective pharmaceutical preparations. The main products are analgesics/anti-rheumatics, antibiotics, dermatics, diuretics, drugs to stimulate blood circulation, drugs for treatment of gastro-intestinal disorders, vitamins, expectorants, lipid-lowering agents, ophthalmics, cosmetics, food supplements, diet foods and foods.	medphano.de

Pharmaceutical Companies		
MUCOS Pharma GmbH & Co.KG	As a specialist in enzyme preparations Mucos supplies a steadily growing market with specific and variably dosed enzyme combinations. The company leads the world market in oral enzymes for therapeutic purposes.	mucos.de
Nycomed Oranienburg GmbH	As the competence centre for the development, production and packaging of solid dosage formulations Nycomed Oranienburg plays an important part in the global Nycomed operations network. It supplies the global pharmaceutical markets in more than 100 countries, from Europe to the US and Japan. The products include corporate Nycomed products and contract manufacturing for third parties.	nycomed.de
Pfizer GmbH	Pfizer is the world's largest research-based biomedical and pharmaceutical company.	pfizer.de
Sanofi-Aventis Deutschland GmbH	Sanofi-aventis is a leading global pharmaceutical company based in Paris and operating in over 100 countries. R&D teams work on a global approach to patients, offering innovative therapeutic strategies in thrombosis, cardiovascular diseases, diabetes, vaccines, oncology, the central nervous system disorders and internal medicine.	sanofi-aventis.de
Shire Deutschland GmbH	Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder, human genetic therapies and gastrointestinal diseases.	shire.com
Steiner & Co. Deutsche Arzneimittelgesellschaft mbH & Co. KG	Production and marketing of pharmacy and prescription drugs, particularly plant-based drugs (tranquillizers, rheumatism drugs, bile duct and gastro-intestinal as well as gynecological and urological drugs), analgesics and mineral preparations.	steinerarznei-berlin.de
Steripharm Pharmazeutische Produkte GmbH & Co. KG	Production and marketing of folic acid products	steripharm.de
Contract Manufacturers		
Advance Pharma GmbH	Contract manufacturer of solid drugs. Galenic development and admissions, analytics and microbiology, coating and granulation (organic and aqueous), compacting, packaging.	advance-pharma.eu
ALPHAMADE GmbH	Customized formulations as medications: parenteral feeding, intradialytic parenteral feeding, omega-3 fatty acids, cytostatics	alphamade.de
Ayanda	Ayanda is an innovative business partner and manufacturer of consumer ready pharmaceuticals and food supplements. In Pritzwalk, Brandenburg, the company has a pharmaceutical soft gel encapsulation plant.	ayanda.com
Chemisch-pharmazeutisches Labor, Rolf Sachse GmbH	CPL SACHSE offers: Custom synthesis development of active pharmaceutical ingredients (API's); Contract manufacture of active pharmaceutical ingredients from laboratory to kiloscale; Pharmaceutical analysis	cpl-sachse.de
Haupt Pharma AG	With nine production sites Haupt Pharma is one of the leading contract manufacturers for pharmaceutical products in the world today. About 2.000 employees produce for an established clientele of more than 200 important international pharmaceutical companies, amongst which 15 of the international TOP 25.	haupt-pharma.de
Pharma Action	Pharma Action has extensive expertise in global pharmaceutical marketing and manufacturing since 1988 and offers cutting edge API solutions to the pharmaceutical industry in Europe and abroad.	Pharma-action.com
Spreewälder Arzneimittel GmbH	Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food supplements, diet foods and cosmetics in liquid, semi-solid and solid administration forms.	spreewaelder-arzneimittel.de
Contract Research Organisations		
AMANTEC GmbH	Since 1999, Amantec has been supporting companies in planning, coordinating and conducting clinical trials. The services provided include trial design, consultation for realization of clinical projects, project management, application and report to authorities, site selection, international contracting, monitoring, data management and, in cooperation with their international partners, medical writing, metrics development, biostatistical analysis, pharmacovigilance as well as the complete drug handling/support	amantec.de
Assign International GmbH	Assign International in Berlin is part of the Assign Group, a mid-sized full-service CRO with six offices in five countries. Our expertise meets development requirements of pharmaceutical and biotechnological industries. We manage clinical trials from study set-up to final clinical report. Our services, among others, comprise Data Management and Biostatistics, integrated EDC-Systems, Pharmacovigilance, Protocol Writing, Laboratory Services and Quality Management.	assigngroup.com

Contract Research Organisations

BLS Preclinical Services	BLS Preclinical Services is a contract research organization (CRO) located in Berlin. BLS provides a range of high quality and integrated preclinical services in animal models. Through our highly skilled scientific partners we provide a "one-stop" service and tailored solution. We take the time to understand your business needs and provide comprehensive tailored solutions either in-house or in co-operation of our network. We are backed by a highly skilled scientific team with a wealth of experience in all disciplines of preclinical development.	bls-germany.com
Charité Research Organisation GmbH	Based in Berlin, the Charité Research Organisation (CRO) was founded in collaboration with Berlin's famous Charité University Hospital. This relationship fosters a level of cooperation with centers of clinical excellence that we think is unique in the industry. The CRO offers a whole new approach to the concept of partnering with centers of clinical excellence to facilitate access to patients, clinical expertise and specialist methodologies in support of early clinical development programs.	charite-research.org
Cooperative Clinical Drug Research and Development (CCDRD) AG	CCDRD is an independent contract research organization (CRO). CCDRD is dedicated to offer creative and innovative full service from planning to market authorization to its customers in the pharmaceutical, biotechnological and medical device industry.	ccdrdag.com
CSG Clinische Studien Gesellschaft mbH	Since its foundation in 1998, the CSG Clinische Studien Gesellschaft mbH has focussed on aligning clinical research with public health demands, with special attention to facilitating access by physicians and patients to clinical studies. CSG cooperates closely with the largest research institute for public health in Germany, the IGES Institut.	csg-germany.com
Dr. Notghi Contract Research	Dr. Notghi Contract Research GmbH is a service provider for large, medium and small-sized companies in the pharmaceutical, generics and biotechnology industries. We support and advise you in the conduct and management of national and international projects.	notghi.com
Klinische Forschung Berlin GbR	Klinische Forschung Berlin is a study centre that implements clinical studies from phases IIA to IV for the pharmaceuticals industry.	klinische-forschung-berlin.de
Klinische Forschung Gruppe Nord GmbH	The Klinische Forschung Gruppe Nord (Clinical Research Group North) is a network of independent investigator institutes with five centres in Northern Germany, two of them in Berlin. The Klinische Forschung Gruppe Nord has carried out trials with up to 250 patients. Phase II and III studies are the core competence. The test centres have altogether 30 overnight accommodation places for phase I and IIa studies.	kfgn.de
PAREXEL International GmbH	The German subsidiary of the US clinical research organization PAREXEL employs more than 1,400 people in Berlin. In two units with a 160-bed capacity (incl. 8 sleep lab beds) and an annual enrollment of approximately 2,500 volunteers in Berlin, more than 75 clinical studies are performed each year.	parexel.com

Biotech Companies

3B Pharmaceuticals GmbH	3B Pharmaceuticals GmbH (3BP) is a privately held pharmaceutical R&D company based in Berlin, Germany. The company is dedicated to the development of peptide-based pharmaceutical- and diagnostic products. 3BP is pursuing projects in hemophilia and nuclear medicine.	3b-pharma.com
8sens.biognostic GmbH	8sens.biognostic develops, produces and sells rapid tests (lateral-flow) and ELISAs for different markets (human and veterinary diagnostics, food control). Our products are the QuickSens®-tests for h-FABP, Tropl, CRP and hs-CRP and the Reader for quantification QuickSens®OMEGA. Development-on-demand, feasibility studies and production-on-demand are also offered.	biognostic.de
ABITEP GmbH	The ABITEP GmbH is working in development and production of biotechnological products for sustainable agriculture. The team of ABITEP works for development of non GMO customer specific technologies in laboratory scale and scale up with modern equipment and Know how. Capacities for fermentation up to 5.000 L, down stream equipment as well as freeze drier with capacity of 90 L are available for services. A molecular biology lab is available for basic science.	abitep.de
Aevotis GmbH	The core competencies of aevotis lie in the targeted conversion of simple carbohydrate containing substrates (e.g. agricultural by-products, waste streams, inexpensive sugars) to high-value carbohydrate based products, their characterization, processing and testing. Marketable products include novel /optimized enzymes, expression systems, specialized biotransformation and down-stream processes, customized oligomers and polymers for food and non-food uses.	aevotis.com
AFOSA GmbH	Development, production and marketing of diagnostics (ELISA kits), primarily for use in veterinary medicine	afosa.com
Aglycon Mycoton GmbH	Aglycon Mycoton GmbH is active in the research, development and application of biopolymers as well as their manufacture and the sales and marketing of products based on these.	aglycon-mycoton.net
AJ Innuscreen GmbH	AJ Innuscreen GmbH, a young life science company, boosts the bio solutions business unit as part of the Analytik Jena Group. Innovative technologies and products are developed and produced for the isolation and purification of nucleic acids. Reagent systems for molecular biology, as well as technologies and products for molecular diagnostics, are also included in the product portfolio.	innuscreen.com

Biotech Companies		
Alacris Theranostics GmbH	The company generates genome and transcriptome data from clinical tumor samples via next generation sequencing. Data are subsequently analysed by the Systems Biology Modelling System a software based technology platform developed at the Max Planck Institute for molecular Genetics which is exclusively licensed to Alacris. The system is used to select an optimised personalized therapy depending on the genetic and expression profile of the tumor. From such profiles and from large quantities of data, patient groups and relevant disease biomarker are identified.	alacris.de
Alcat Europe GmbH	Alcat Europe GmbH is the daughter of the US company Cell Science Systems, the original developer of the Alcat test technology. The company is specialized to identify intolerant reactions of the leucocytes to foreign substances like foods, drugs or chemicals.	alcat-europe.com
Alrise Biosystems GmbH	ALRISE is a drug delivery company that specializes in the nano- and micro-encapsulation of active ingredients. Using its globally patented ImSus® technology, ALRISE are developing parenteral deposit pharmaceutical forms for proteins, peptides or small molecules. Customers are mainly large pharmaceutical companies who are developing improved administration forms for active ingredients whose patents are expiring together with ALRISE as part of their "Product Lifecycle Management".	alrise.de
Amocol Bioprocedures Ltd.	Amocol Bioprocedures Ltd is a Life Science Research & Development and Manufacturing Company headquartered in Germany. Our mission is to supply innovative affinity chromatography media products and protein purification tools for research scientists and clinical customers in public sector institutes and industry.	amocol.com
AnaKat Institut für Biotechnologie GmbH	AnaKat Institut für Biotechnologie GmbH has specialized on analytical determination of pharmaceutical ingredients.	anakat.de
Analyticon Discovery GmbH	AnalytiCon is a biotechnology company focusing on the development of compound libraries consisting of natural product (NP) and synthetic small molecules. As the global market leader in NP small molecule screening compounds, AnalytiCon is the only company which is able to provide vast collections with completely disclosed structural information. As a pure compound provider the company is offering its products and services to the pharmac., chemical, biotech, cosmetic and nutraceutical industry.	ac-discovery.com
Analytisches Zentrum Biopharm Berlin GmbH	Analytisches Zentrum Biopharm GmbH Berlin is a contract research organization providing services on pharmaceutical analysis and bioanalysis for active compounds in the dosage form, for the quantitative determination of analytes in a biological matrix and also the determination of physicochemical parameters of chemicals according to OECD guidelines. AZB carries out these services in compliance with GLP and GMP and has the GLP certificate.	analytisches-zentrum-biopharm.de
AnaTox GmbH & Co. KG	The AnaTox GmbH & Co. KG deals with the development and optimization of analytical methods and devices for HPLC and dissolution.	anatox.de
Anau Berlin-lab GmbH	Development and distribution of lab devices	eurolab24.com
ANIMOX GmbH	Development of applications for the use of natural peptide / amino acid mixtures in chemistry and biotechnology, f. i. as a scavenger material in formaldehyde bounded formulations, foaming or hydrophobic Tensid compounds or as a N-source in biotechnological fermentation processes, distribution of a technology for the production of such basic materials from raw and residual materials.	animox.de
Aokin AG	Aokin AG is a Berlin biotechnology company that is specialized in the development and commercialization of innovative analytical systems on the base of the rapid kinetic assay technology. The aokin systems are unique in their precision and operating speed. Areas of application are food and antibody analytics as well as clinical diagnostics. We also offer laboratory services in the area of food analytics, Pharmacodynamics and chemical synthesis.	aokin.com
AptaRes AG	AptaRes is a developer and manufacturer of aptamers as an alternative to antibodies. The aptamers are isolated in vitro by using a proprietary technology. AptaRes is also developing aptamer-supported processes and analytical methods. It provides also consumables required for the aptamer applications. In collaboration with financial partners AptaRes supports with its enabling technology entrepreneurs and the expansion of biotechnology companies.	aptares.de
ARGUS Umweltbiotechnologie GmbH	ARGUS is a medium-sized company. Since 1987 ARGUS works on the field of remediation of contaminated groundwater, soil, waste water and waste air. ARGUS is able to elaborate a specific remediation program in each different pollution case considering economic aspects beside ecological aspects. All necessary treatment steps can be planned and carried out. The combination of microbiological steps with classic processes leads to a successful remediation of complex contamination.	argus-umwelt.de
ASCA GmbH Angewandte Synthesechemie Adlershof	ASCA is a partner for contract research in the field of medicinal chemistry. The synthesis and optimization of lead structures, the development of new active structures and their check on a laboratory scale are offered. We take a lot of care on working out the synthetic schemes, rapid preparations and exact analysis of the samples. All our results are carefully documented for our customers. Access to literature databases and in-house analytical facilities are available.	asca-berlin.de

Biotech Companies		
Astra Biotech GmbH	The Company Astra Biotech offers a wide range of high-quality reagents and diagnostic kits. The catalogue provided by our company includes reagents for detecting of human hormones, genetic diseases, tumor markers and allergens. Besides, we develop cutting-edge, technologically perfect solutions in the field of diagnostics and we are ready to offer our experience, skills and knowledge for realization of your projects.	astrabiotech.de
ATLAS Biolabs GmbH	ATLAS Biolabs GmbH is a leading provider of microarray based genomic services such as genome wide gene expression and SNP analysis, CGH analysis and diagnostic services for registered doctors and hospitals, as well as for pharmaceutical, biotechnological and diagnostic enterprises.	atlas-biolabs.de
Attomol GmbH Molekulare Diagnostika	The company's aim is to develop, produce and distribute medical diagnostics for human medicine in the field of molecular genetics, infectious and autoimmune diseases.	attomol.de
AutoTissue GmbH	The company is engaged in the development, production and marketing of medical devices for cardiovascular surgeons. The products are specially made for the patients and have less side effects. The first certified product was a pulmonary heart valve (Matrix P) for the right ventricular outflow tract reconstruction (RVOT). The second product is also a heart valve which considerably shortens the operation time (Matrix P plus). Meanwhile a complete glutaraldehyde free valve is available called Matrix P plus N.	autotissue.de
B·R·A·H·M·S GmbH	B·R·A·H·M·S explores, develops and produces new diagnostic test procedures to improve the diagnosis, and thereby the treatment, of life-threatening illnesses. This takes place with over 400 employees, in the disease areas infectiology, thyroid, autoimmunity and cardiology on the basis of our own patented biomarkers. Since October 2009 B·R·A·H·M·S is part of Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science.	brahms.de
Bavarian Nordic GmbH	Bavarian Nordic is a leading international biopharmaceutical company developing, producing and marketing innovative vaccines to prevent and treat infectious diseases and cancer.	bavarian-nordic.com
Bbi-biotech GmbH	In the focus of the activities of bbi-biotech lie systems for the sterile sampling from bioreactors for all applications in the biotechnology, pharmaceutical, food, cosmetics and chemical industry. In addition, bbi-biotech develops components – in especially disposable ones – for the preparation of a new generation of fermentors and bioreactors and offers consulting and planning services for biotech projects, its implementation and services.	bbi-biotech.com
BEB BioEnergy Berlin GmbH	Planning, Design, Construction, Supervision and Implementation of Biogas/Hydropower plants, Preplanning, Feasibility Studies and Research activities in the field of renewable energies, Optimization of the process in existing biogas plants	bebgmbh.de
BG Berlin-Genetics GmbH	BG Berlin-Genetics GmbH is a new provider for genetic diagnostics and consulting in genetic diagnostics. We are a team of experienced human geneticists and have worked for many years in the field of human genetic science and human genetic diagnostics. Our aim is the development of innovative cooperation concepts, to connect classical patient-based medical care centers with modern technology-based service centers. In future, these cooperation forms will enable efficient, high quality, and patient-based genetic diagnostics.	bg-berlin-genetics.de
Bioanalyt GmbH	Bioanalyt, a 2006 founded spin-off of the University of Potsdam, is committed to develop easy-to-use and portable test kits for the analysis of fat-soluble vitamins. The iCheck-iEx system is an innovative technology to measure carotenoids and/or vitamin A in biological fluids and food. The analysis of one sample is performed in a few minutes and is low-priced compared to traditional laboratory methods. Read more on our website www.bioanalyt.com.	bioanalyt.com
Bioassays GmbH	Service related to the development of medical in vitro diagnostic products. Basic science to clinical development. Profiling of biomarkers in clinical trials.	
Biochrom AG	Biochrom is Germany's largest manufacturer of cell culture products (media, sera, and others). They are distributed to universities, industrial cell culture laboratories and industrial manufacturers. Service is of special significance for users of cell cultures. Special media developments and production optimizations are offered.	Biochrom.de
BIOCYC Gesellschaft für Biotechnologie und Recycling mbH & Co.KG	Production of bio-chemicals, peptides, in-vitro-diagnostics, test-kits. Development of consumer service for peptides and biochemicals.	quartett.com
BioGenes GmbH	BioGenes is a full service immunoassay and antibody (monoclonal and polyclonal) development company with outstanding problem solving capabilities specializing in challenging projects that are carried out by an exceptionally experienced and interdisciplinary team.	biogenes.de
Bioline GmbH	Our mission is to provide customers with a range of products which are fast and easy to use, guaranteed to work and developed by scientists who understand what our customers are trying to achieve so they can focus on their scientific goals. Bioline reagents are used by molecular biologists and other research scientists to perform test-assays and research in many fields from medical, biotechnology and marine biology to food and agriculture technology as well as forensic and environmental sciences, where life scientists have come to depend upon the outstanding quality and reliability of our reagents.	bioline.com
BioMedion GmbH	IT-Service for all GxP-Regulatory Tasks Data- and Document Management, Long-Term-Archiving and Digital Signature, SOP-Management, CAPA, Raw Data Management, Consulting for Validation of Computerized Systems according to GAMP4/5	biomedion.com

Biotech Companies		
Biorefinery.de GmbH	Based on main precursors of plants, carbohydrates in kind of sugar, starch and cellulose, and proteins, the biorefinery.de company has developed four complex product lines (Biorefinery systems) which leads to a great number of valuable products with the help of chemistry and biotechnology.	biorefinery.de
BioRepro GmbH	BioRepro is the first pharmac. company, whose core competency is the breeding of leeches under controlled laboratory conditions for medical therapies. We concentrate on the establishment of GMP breeding procedures and will be able to provide leeches with standardized quality while equally allowing scalability to supply medical demand. Additionally, through the re-initiation of fundamental research, we will gain deeper understanding of further potential in medical and cosmetic treatment areas.	biorepro.de
BioS Biotechnologie Schönow GmbH	Embryo transfer and associated biotechnologies in animals. Service, training and research in this field.	bios-schoenow.de
BioSilta Europe GmbH	BioSilta is an international company that specializes in advanced tools for microbial cell cultivation, protein production, enzyme screening and food spoilage testing. The patented EnBase® technology resembles fed-batch mode and provides a cultivation environment with glucose-control, pH maintenance and inhibition of growth-limiting metabolites without the need for traditional mechanical pumps. EnBase® is provided in ready-to-use liquid or tablet products. BioSilta specializes in small-scale cultures and its products offer customer solutions from multi-well plates to small-scale bioreactors. Learn more about our products and applications at www.biosilta.com .	biosilta.com
BIOSYNTAN Gesellschaft für bioorganische Synthese mbH	BIOSYNTAN offers the custom synthesis of standard peptides, the synthesis of modified peptides (e. g. glyco- and phosphopeptides, dye labeled peptides) and hapten modifications for the conjugate synthesis. In cooperation with BIOGENES GmbH Berlin we offer poly- and monoclonal antibodies.	biosyntan.de
Biotech-Laboratorium für Environment BLE GmbH	Development of detection systems which are able, economically and rapidly, to detect oil contaminations and industrial oil waste, in soil and in water and their biological depletion. The BLE GmbH is concerned with the biological degradation of oil contaminations and the development of a set of bio-preparations consisting of different bacterial strains which break down oil.	
BIOTECON Diagnostics GmbH	BIOTECON Diagnostics has been well known as a qualified partner in the field of molecular and microbiology for the last 12 years. We focus on development, production and marketing of PCR-based rapid detection systems. BIOTECON Diagnostics offers solutions for the food and beverage industry as well as for producers of pharmaceuticals and cosmetics.	bc-diagnostics.com
BioTeZ Berlin-Buch GmbH	Services: Custom oligonucleotide synthesis, immuno affinity columns. Development of enzyme immunoassays, e. g. for therapeutic antibodies-immobilization of biomolecules for better signalling. R&D (Aptamer)	biotez.de
BIOWORX -Biotechnologielabor- Thomas Grimm	BIOWORX offers services in the fields of contract research for customer-specific Biotransformations, the screening, isolation and production of Biocatalysts from microorganisms and plants and the bioanalytic syntheses. Further organic compounds and metabolites will be synthesized with enzymes for customer in kg scale.	bioworx.de
BiRDS Pharma GmbH	BiRDS Pharma GmbH, integrated into the BDD/CCDRD group, provides services in the field of drug development to pharmaceutical and biotech companies, including management of drug development projects as well as consulting services. The company also pursues own drug development projects based on intellectual property generated within BDD/CCDRD group, with a focus on drug candidates derived from Atomic Substitution Technology (AST).	birdspharma.com
Botiss medical AG	Botiss biomaterials is a privately owned biotech company, headquartered in Berlin. botiss is the leading German specialist for dental bone and tissue regeneration (BTR). We focus on the development of innovative regenerative materials and clinical marketing / distribution in over 50 countries world-wide. The botiss subsidiary Cell+Tissue Bank Austria is a leading European manufacturer of allogenic materials for hard tissue regeneration.	botiss.com
Breecon GmbH	The breecon GmbH is an innovative service company in life science with focus on green biotechnology. The objectives of the company are consulting, application and mediation of biotechnological-analytical services as well as their development and marketing. The breecon GmbH offers his services to plant breeders and companies of the industrial biotechnology and supports the utilization of genetic diversity in the context of SMART breeding.	breecon.com
BST Bio Sensor Technology GmbH	BST develops and produces biosensors to provide high quality analysis at moderate prices. In 1982 BST brought on the market the first multi-way biosensor based blood glucose analyzer in Europe and is since then market leader in Europe. Today BST sells more than 60.000 sensors a year. Since 2008 BST is besides biosensors also manufacturer of POCT and laboratory instruments.	bst-biosensor.de
Caprotec bioanalytics GmbH	Caprotecs Capture Compound Mass Spectrometry (CCMS) Technology allows to separate and identify proteins based on functionality. For many applications, CCMS is clearly superior to conventional methods - thus addressing an unmet need in the proteomics research community. The company develops caproKits for proteomics research and plans to enter into collaborations with the pharmaceutical industry for small molecule / drug optimization and development.	caprotec.com

Biotech Companies		
Capsulation Pharma AG	Capsulation Pharma AG develops innovative nano- and micron-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules (500 nm to 50 µm) can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer.	capsulation.com
Cavira GmbH	Cavira is active in the field of infectious diseases and oncology. For the time being two products are in preclinical stage with encouraging in vitro and in vivo data. One product is a derivate of a well known chemotherapeutic. The other one is combination therapy based on the amino acid depleting enzyme Histidinase with broad potential in both, oncology and infectious diseases. Research and development are conducted in cooperation with very well known universities or contract research organizations.	cavira.de
Celares GmbH	Specialist for Drug Delivery of peptides/proteins by using PEGylation. Modification of Bio-pharmaceuticals with polyethylene glycol in order to substantially improve pharmacological properties. Offers the unique CelaSYS-PEGylation technology, which is patented by celares. CelaSYS: non-dispersed, highly branched polyethylene glycol based reagents. Additionally celares offers customized PEGylation solutions as well as synthesis of customized PEG-reagents.	celares.com
CellServe GmbH	CellServe is a service provider for research groups in regenerative medicine, especially in the production, functional characterization and monitoring of cells as therapeutic agents and research tools, each in accordance with the most recent regulatory guidelines and cGMP standards. With its services and products, the company fills an important gap in the conversion of applied treatment concepts from research into marketable products.	cellserve.de
CellTrend GmbH	Celltrend is certified according to ISO 9001, ISO 13485 and GMP. The company offers cell culture systems for research on active substances (bioassays, preclinical research, for quality control), development and production of antibody-based detection systems (ELISA), chemosensitivity assay for optimisation of chemotherapy (tumor patients)	celltrend.de
Chemicell GmbH	Chemicell develops and produces magnetic, fluorescent and coloured nano- and microparticles, reactive fluorescent dyes and special chromatography-materials for the separation or detection of cells, bacteria, viruses, proteins or DNA/RNA and new gene transfer systems.	chemicell.com
Chipron GmbH	Chipron GmbH specializes in production and distribution of array based detection systems for DNA / pathogens	chipron.com
CHIRACON GmbH	chiracon is a qualified partner to develop chiral intermediates at a constant high quality for innovative drugs regarding economic, environmentally acceptable and scaleable aspects. We offer support through expert knowledge and key technology to meet your increasing needs. Our core competence is chirality. In addition we have a broad variety of chiral building blocks as an inhouse raw material source for high-level API production and development.	chiracon.de
CMZ-Assay GmbH	Marketing of diagnostic reagents for measuring concentrations of proteins, hormones and their isoforms, exclusively for research purposes.	cmz-assay.com
Co.don AG	Co.don® AG is one of the leading biopharmaceutical companies in the area of Regenerative Medicine/Tissue Engineering. Since 1997, co.don® AG has developed, manufactured and distributed human Tissue engineering therapeutics for the regeneration of articular cartilage, bone and intervertebral discs.	codon.de
CompoundSelect	CompoundSelect offers customized compound databases, consisting of e. g. medicines, natural compounds or scents. The databases are provided with a variety of screening options, a comfortable usability, physico-chemical properties and additional information such as availability, supplier and functional features for each compound.	bioinformatics.charite.de/ compoundselect
CONGEN Biotechnologie GmbH	CONGEN is specialized in food testing by molecular analytics based on DNA and RNA detection. CONGEN has been a pioneer for over a decade in the development and application of food and feed analytics by real-time PCR. The methods are available as complete analytic kit as well as a Service. Our mission is to serve the food industry with an excellent service and with standardized and reliable test kits in order to realize highest possible food safety and food quality.	congen.de
CREATOGEN Laboratories GmbH	Development of vaccines for application in veterinary and human applications.	
Cyano Biofuels GmbH	The company focuses on the biotechnological use of cyanobacteria, especially the development and optimization of cyanobacteria for the production of environmentally friendly biofuels and chemical feedstocks.	cyano-biofuels.com
Cyano Biotech GmbH	Cyano Biotech identifies and characterizes natural products from cyanobacteria and optimizes their pharmacological activities employing a biocombinatorial approach. The company conduct further development of identified lead structures till the preclinical phase.	cyano-biotech.com
Diaglobal GmbH	Development, production and distribution of in-vitro-diagnostics for analytical purpose and the distribution of medical products.	diaglobal.de

Biotech Companies		
DIZG Deutsches Institut für Zell- und Gewebersatz gemeinnützige GmbH	DIZG German Institute for Cell and Tissue Replacement engages in cell and tissue preservation as well as in cell and tissue replacement, and provides tissue preparations of human origin to clinics, teaching and research organisations. Further service is culturing of skin cells (keratinocytes) for serious burns and other skin defects not healing well or affecting large areas. DIZG supplies cell cultures to help avoid experimentation with animals e.g. in the cosmetics industry.	dizg.de
Dr. Götz Verfahrenstechnik Biotechnik Umwelttechnik	Contract research and contract manufacturing using bacteria, yeasts and fungi.	drgoetz.de
Dr. Lerche KG	Innovative company engaged in development, production and marketing of specialized microcapsules for bio- and medical technology – Development and production of novel DNA-Purification-Kits with proprietary technology – Production and marketing of microcapsules (LUMITainer), microbeads and cell based sedimentation standards for blood analysis (Sedi-Val ESR standards) – Encapsulation of cells – Contract analysis for characterization of microcapsules, porous membranes and hollow fibres	lerche-biotec.com
Dr. Otto GmbH	Handling with research and development of ecological products its process of development also its production and marketing – Production and refinement of plantingredients – Operate an analytical laboratory of renewable resources and chem. Analysis	dr-otto-gmbh.de
Dr. Rölleke Labor für Genetische Analytik GmbH	Dr. Roelleke is specialized on the identification of microorganisms, particularly in the area of food safety. Furthermore, Dr. Roelleke is authorized expert on paternity tests for courts and the private sector.	dr-roelleke.de
DSM Biopract GmbH	Service and Additives (enzymes, trace elements, microbes) for biogas and waste water sludge treatment Enzyme analysis in Food and agriculture industry Contract research feed additives	dsmbiogas.com
Durakult	Die durakult GmbH entwickelt und optimiert als Dienstleister mikrobielle Starterkulturen und Biokatalysatoren für die biotechnologische Produktion von Lebensmitteln und Chemikalien auf Basis von Biofilmen. Die unserer Dienstleistungen zugrunde liegende Plattformtechnologie ist das zum Patent angemeldete durakult®-Bioreaktorsystem. Darüber hinaus bieten wir eine Reihe von mikrobiologischen Dienstleistungen wie z.B. die Herstellung von Starterkulturen oder troubleshooting bestehender Prozesse an.	public@durakult.de
E.R.D.E.-AAK-Diagnostik GmbH	E.R.D.E.-AAK-Diagnostik GmbH is a laboratory that offers antibody testing for commercial purposes.	aak-diagnostik.de
Eckert & Ziegler AG	Eckert & Ziegler Strahlen- und Medizintechnik AG, headquartered in Berlin, is a globally active isotope technology company and holding company for a number of specialised subsidiaries that process radioisotopes as well as develop, manufacture and sell isotope technology components, medical technology equipment and related products.	ezag.de
EMP Biotech GmbH	Production of fluorescent dyes and chemiluminescent reagents. Contract chemical synthesis of small molecules. Contract labeling and purification of proteins, antibodies and oligonucleotides. Production of size-exclusion gels, columns and filter plates. Production of high quality reagents for DNA synthesis.	empbiotech.com
Epigenomics AG	Development and commercialization of innovative molecular diagnostic test products based on DNA methylation for cancer screening and for cancer specialty applications.	epigenomics.com
Epinamics GmbH	Epinamics GmbH, a newly established Berlin based pharmaceutical research and development dedicated company, is owner of a proprietary film forming formulation technology platform, the "Invisible Patch" system. The system is offering a broad basis for the development of formulations for treatment of dermatological diseases as well as for the development of transdermal systems.	epinamics.com
Epiontis GmbH	Establishing methylation fingerprinting as Gold Standard for quality control in Regenerative Medicine and Immunomonitoring.	epiontis.com
Epo Experimentelle Pharmakologie & Onkologie GmbH	The pharmaceutical and oncological testing of new drugs or treatment concepts for cancer is a specialized market segment. Using the equipment available, all experimental and animal experiment techniques can be carried out in first-rate quality. That means that EPO is an attractive partner for the drug development section of large pharmaceutical companies, for partners from the Biotech industry and for research institutions.	epo-berlin.com
Eurovir Hygiene-Institut/Dr. Thraenhart	Laboratory service for testing the efficiency of products against viruses (virucides) and of processes for inactivating or eliminating viruses (virus safety)	eurovir.de
EVESTRA GmbH	EVESTRA is a newly founded biotech company focusing on developing female health products. The companies expertise resides with steroid chemistry and biology. EVESTRA's product pipeline includes products for contraception, hormone replacement therapy, gynecological disorders and hormon dependent cancers.	evestra.com
Evotec AG	Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programs and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries. In proprietary projects,	evotec.com

Biotech Companies		
F.A.T. Forschungsinstitut für Antioxidative Therapie GmbH	Measuring instruments and kits for evaluating the antioxidant properties and the degree of oxidative damage in biological substrates	antioxidant-research.eu
Fermtec GmbH	Development of non-alcoholic beverages, beers and beer mix beverages, lactic acid fermentation, innovative foods and beverages and auxiliary substances for the food industry	fermtecgmbh.de
Ferropharm GmbH	Development of very small super para-magnetic nano particles as contrast agent for MRI	ferropharm.de
FILT Lungen- und Thoraxdiagnostik GmbH	Development of innovative, non-invasive diagnostic methods in the area of respiratory diseases and allergies	filt.de
Formula GmbH	Galenical development of liquids and solid formulations. Lyophilization Technology also applicable for biochemical products. Granulation, drying and coating using fluid bed drying-technology, tableting. Development and validation of analytical methods including UPLC. Stability testing (ICH / GMP related to on going). Import of medicinal products from non-EU-countries, manufacturing, quality control (re-test) and release for market in accordance with §16 AMWHV for medicinal products and clinical supplies. GMP-certificat / Manufacturing license in accordance with §13 AMG.	formula-pharma.de
GA Generic Assays GmbH	Development, manufacturing and distributing of in-vitro-tests, focussing on autoimmune diseases, hereditary and infections diseases.	genericassays.com
Gene Analysis Service GmbH	Gene Analysis Service is specialized on genetic testing of a number of rare hereditary diseases and provides nucleic acid based molecular biological services like PCR and custom DNA sequencing for healthcare providers and research institutes worldwide.	gene-analysis-service.de
GenExpress Gesellschaft für Proteindesign GmbH	GenExpress is a flexible company providing services in molecular biology. For over a decade we have successfully worked for customers in clinical laboratories, research institutions and the industry. We offer cloning of PCR targets, preparation of synthetic genes, expression of proteins, evaluation of LightCycler® assays, furthermore production of internal controls and standards for Real Time PCR systems, also cloning, expression and purification of proteins.	genexpress.de
GILUPI GmbH	GILUPI is a medical diagnostics company with an initial focus on the prenatal and cancer market. The company is developing an innovative new diagnostic product based on nano-technology. Our goal is to catch specific cells, which can be found only in very low concentration in the blood. The first application for our new nanosensor device will be prenatal diagnoses of chromosomal aberration out of maternal blood. The second application will focus on the early diagnosis of cancer.	gilupi.com
GlucoMetrix PVS GmbH	The GlucoMetrix AG focuses on the early detection and management of diabetes mellitus-aftermath. At the foreground of research and development is the enhancing the quality of life of diabetics. In addition, the life science company develops some IT-based diagnostic procedures and medical devices as well as biopharmaceuticals and other highly effective products in order to raise the quality of life of diabetics sustainably.	glucometrix.de
Glycon Biochemicals GmbH	Production of carbohydrate components used for the synthesis of new pharmaceutical compounds or diagnostics	glycon.de
Glycotope GmbH	Glycotope is a leading company in glycomics and immunotherapeutics. It has developed novel therapeutic antibodies and unique platform technologies to optimize the glycosylation of new biological entities. Glycotope Biotechnology, with 25 years of experience in GMP-production, enables us to offer the entire process of biopharmaceutical development with a dedicated focus on our unrivalled expertise in protein glycosylation from the gene to production and fill & finish of clinical grade material.	glycotope.com
Götz Protein Engineering	Offering a wide range of protein technology up to the final purified protein	goetz-protein-engineering.de
HealthTwist GmbH	HealthTwist is a service provider for "Genetic Contract Research" in the fields of Functional Genomics, Pharmacogenomics, Proteomics or Functional Food / Nutraceuticals. In particular, HealthTwist is offering access to extensively characterized human subjects and samples as well as prospective studies in twins, together with know-how in the analysis of complex genetic traits. Furthermore, database development, data management and statistical analyses for clinical projects are provided.	healthtwist.de
HF Biotec Berlin GmbH	Development, selling and operating of digestion plants using liquid substrates of industrial and agricultural provenience, Development and operating of combined plants to upgrade biogas into bio methane useable in public gas grids with parallel production and selling of high quality PCC, Development of innovative biotechnological processes and plants.	hf-biotec.com
Human BioSciences GmbH	The biotech-company Human BioSciences Inc. is specialized in manufacturing and distribution of modern collagen based wound and skin care products.	HumanBioSciences.de
HUMAN GmbH	For over 35 years HUMAN has been serving the healthcare sector. HUMAN develops and manufactures in Germany laboratory diagnostic products for the world market. HUMAN stands for quality and service in over 160 countries. In our new competence centre for autoimmune diagnostics, an expert team of highly specialized scientists and technicians develop and produce the IMTEC product line, a range of high-quality autoimmune diagnostic products. Further innovative products are to be launched soon!	human.de

Biotech Companies		
Icon biotech	Icon biotech is an innovative biotechnology company, which uses the extraordinary characteristics of Ciliates for the development of bio-analytical and toxicological model systems.	icon-biotech.com
Ifp Institut für Produktqualität GmbH	The ifp Institut für Produktqualität is an independent laboratory and competence centre for state-of-the-art food analysis and -diagnostics. We analyse the composition and quality of food products. An additional core competence of ifp is the development and production of innovative diagnostics comprising vitamin tests, real-time PCR based detection systems, e. g. for allergens or pathogens and immunological rapid tests for allergen detection.	produktqualitaet.com
IGV Institut für Getreideverarbeitung GmbH	The range of services offered by the Biotechnology Division of the private research IGV GmbH institute is based on 25 years of experience in R&D for the cultivation of phototropic micro-organisms. Excellent, world-wide contacts to biomass producers, food producers, to the pharmaceutical and cosmetics and energy industry provide the foundation for innovative, market-oriented developments. In focus are development of photo bioreactor technology and active substances from algae.	igv-gmbh.de
IKDT Institut Kardiale Diagnostik und Therapie GmbH	IKDT was founded in August 2002 in Berlin-Steglitz and is one of the leading laboratories on Viral Infections of Heart Muscle Tissue and Dilated Cardiomyopathy (DCM) in Germany. IKDT lab is performing a comprehensive molecular diagnostic examination of endomyocardial biopsies as one of a limited number of specialized cardiological labs worldwide. Its service enables physicians firstly to start an efficient, pathophysiologically based causal therapy.	ikdt.de
ILBC GmbH	Research, consulting, production, trade & services in the areas biology, molecular biology and protein chemistry – Expression and production of antimicrobial peptides	mobiclup.de
ImaGenes GmbH	RZPD spin-off, today part of Source BioScience plc, a premier service center for genome research and healthcare in Europe, provides one of the largest clone collections in the world via its clone search engine GenomeCube®. Certified Service Provider for illumina Next Generation Sequencing services and comprehensive microarray application on Affymetrix, Agilent, and NimbleGen platforms. ISO 9001:2008 certified.	imagenes-bio.de
In.vent DIAGNOSTICA GmbH	in.vent DIAGNOSTICA GMBH is a biomedical company. We are focused on the project-oriented provision, processing and distribution of biological raw material for development and production of diagnostics and control material. We are your reliable partner for the customised development of assays for medical in vitro diagnostics.	inventdiagnostica.de
inbion GmbH	inbion GmbH provides services to support research in the interface between university, students and industry. For companies, we provide the benefit of outsourcing projects quickly and cost-efficiently to competent teams. Cooperation with research groups in the university is also facilitated, so that targeted knowledge transfer can take place here.	inbion.de
Innovative Optische Meßtechnik	Fluorescence Assay Solutions and Instrumentation (Microplate Readers)	iom-berlin.de
Institut für Medizinische Molekulardiagnostik (IMMD)	Gene tests for prenatal, predictive and tumor -diagnostics	immd.de
Institut für Molekular- und Systemmedizin I.M.S.M. GmbH	Scientific-practical works in the area of System medicine with the purpose of the patenting of new treatment methods, e. g. to the treatment of diabetes. International cooperation in this area.	
InVivo Biotech Services GmbH	As a contract manufacturing company (CMO) Invivo offers a wide range of services: the development and production of monoclonal antibodies and recombinant proteins for diagnostic and pre-clinical use (endotoxin-free antibodies and compliant documentation), cell line development and transient transfection. We are an ISO9001:2008 certified company.	invivo.de
JPK Instruments AG	JPK Instruments AG is a world-leading manufacturer of nanoanalytic instruments – particularly atomic force microscope (AFM) systems and optical tweezers – for a broad range of applications reaching from soft matter physics to nano-optics, from surface chemistry to cell and molecular biology. From its earliest days applying atomic force microscope (AFM) technology, JPK has recognized the opportunities provided by nanotechnology for transforming life sciences and soft matter research.	jpk.com
JPT Peptide Technologies GmbH	JPT Peptide Technologies GmbH, a wholly owned subsidiary of Theracode GmbH, is a DIN EN ISO 9001:2000 certified biotechnology company based in Berlin and a leading supplier of innovative peptide-based services and products. JPT provides peptide arrays, peptide libraries and specialty peptides.	jpt.com
Klinomed GmbH	Development of new technologies for manufacturing bio-active nano particles / development of therapeutic formulations based on nano particles	klinomed.de
KNAUER – Wissenschaftliche Gerätebau Dr. Ing. Herbert Knauer GmbH	KNAUER UHPLC and HPLC systems as well as columns are used in research and development, quality control and production plant laboratories around the world. Customers are typically governmental and industrial organizations as well as universities. Fields of application are wide-ranging and include pharmaceutical and medical research, analysis of foodstuffs and cosmetics, as well as environmental analysis. With our biochromatography solutions we focus on high resolution separations.	knauer.net
L.U.M. Gesellschaft für Labor-, Umweltdiagnostik & Medizintechnik mbH	Analysis, diagnosis and sensor technology as well as stability, rheology and segregation behavior of dispersions	lum-gmbh.de

Biotech Companies		
Labor Berlin	The company is the service subsidiary of Europe's largest hospital laboratory for clinical pathology and offers complete solutions for any kind of testing for the ivd industry, CROs, the pharmaceutical industry, life science companies and research facilities. Labor Berlin performs over 20 million analyses in clinical pathology per year, it is the exclusive laboratory partner of Charité – Universitätsmedizin Berlin and the Vivantes Network for Health and provides the diagnostics for approximately 9.000 in-house patients a day and over 800.000 out-patients per year.	www.laborberlin.com
LAROVA Biochemie GmbH	Research, development and production of nucleotides, nucleosides, oligonucleotides in natural and modified forms	larova.com
LGC	Production of calibration substances for purity testing of drugs	mikromol.de
LGC Genomics GmbH	LGC Genomics (formerly AGOWA genomics) is the division of LGC with specific expertise in high quality, cutting-edge genomic and related services and products. LGC Genomics delivers: - Next generation sequencing services- DNA sequencing- Genomics services- Nucleic acid extraction services- DNA extraction products LGC is an international science-based company and market leader in analytical, forensic and diagnostic services and reference standards (www.lgc.co.uk).	lgcgenomics.com
Limetec Biotechnologies GmbH	The core competence lies in the development of high-speed and high-quality proof systems for the detection of pathogens, as well as in the allelic discrimination of hereditary diseases. All products are marked with the CE-Certificate. The second area of expertise is the creation of communication networks which connect out-patient and hospital patient treatments, intensify data exchange and provide information to all health institutions, thus establishing partner relationships between them.	limetec-biotechnologies.de
MagForce Nanotechnologies AG	MagForce Nanotechnologies AG is a leader in the area of nanotechnology-based cancer treatment, and the first company worldwide to receive European approval for a medical product using nanoparticles. The company's Nano-Cancer® therapy is a novel therapy for the treatment of solid tumors. Currently, MagForce is preparing for its European product launch, which is expected in early 2011.	magforce.com
Marinpharm GmbH	Development and marketing of genetically altered cell lines on the basis of new fluorescence markers. Generation of stably transfected fluorescent cell lines.	marinpharm.com
Medical Enzymes AG	Medical Enzymes AG is a privately held innovative biopharmaceutical company with a focus on therapeutically useful enzymes. The company has developed a new product family based on amino acid depleting enzymes. This unique approach is highly effective against cancer – the major target market of Medical Enzymes AG.	medical-enzymes.com
MedInnovation GmbH	MedInnovation GmbH has developed a new method and a special ESR-analyser, which for the first time allows a simple routine laboratory test for evaluation of functional characteristics of plasma proteins and further opens a reliable possibility for cancer diagnostic, named MMS-technology (mobility of molecular structure).	medinnovation.de
Medipan GmbH	Development, manufacturing and international distribution of radioactive (125J-IRMA) and non-radioactive (Elisa) in-vitro diagnostic tests, covering the field of Autoimmunity, mainly in Thyroid and Diabetes Typ 1 and automated interpretation of cell-based immunofluorescence tests by the AKLIDES system.	medipan.de
MerLion Pharmaceuticals GmbH	The business purpose of the Company is the research, production, optimization and the development by way of pre-clinical as well as clinical trials of new molecules for the treatment of infectious diseases	merlionpharma.com
Merz Pharmaceuticals GmbH / Standort Potsdam	Merz is one of the leading research-based health care companies. Merz Pharmaceuticals has achieved a leading position in Alzheimer's research with the world's first drug for the treatment of moderate to severe Alzheimer's disease. With high quality products from tete-sept® and Merz Spezial®, Merz is making a key contribution to health and wellbeing.	merz.de
Metabolomic Discoveries GmbH	Metabolomic Discoveries is an analytical service and research company. We provide mass spectrometry based metabolite profiling and fingerprinting of biological material, as well as single compound measurements.	metabolomicdiscoveries.com
Metanomics GmbH	Metabolite Profiling for identification of gene function relationship in plants, metabolite biomarkers and metabolic networks	metanomics.de
Metanomics Health	Identification of metabolic biomarkers for pharmacology, toxicology, diagnostic and nutrition	metanomics-health.de
MetrioPharm AG	MetrioPharm AG develops innovative therapies for infectious diseases on the basis of new and innovative medicines.	metriopharm.com
Mfd Diagnostics GmbH	The mfd Diagnostics GmbH (BT Luckenwalde) is a life science research and development company for diagnostic and therapeutic application of innovative laser technologies. The main advantages of the developed technologies are the non-/minimally-invasive measurement methods, the non-artificial approach and the possibility of real-time measurement. Therefore, those are promising tools for the diagnosis and therapy monitoring in the neurological practice and in the perinatal surveillance.	mfd-diagnostics.com

Biotech Companies		
MicroDiscovery GmbH	MicroDiscovery GmbH is a leading provider of high quality software for biomolecular research, innovative diagnostics and personalised medicine. The company is ISO 9001 certified and has a strong track record in creating software systems in accordance with relevant regulatory directives for the life science and IVD industry. Customised services ranging from biostatistical data analysis to bioinformatical design and support of complex research projects complete the product line of MicroDiscovery.	microdiscovery.de
Microparticles GmbH	Development, manufacture, surface modification and characterization of mono-disperse polymer particles in the nano- and micrometer range. In addition to classic polystyrol and polyacrylate-based polymer particles, microparticles GmbH has launched new melamine resin particles on the market with exceptional chemical and physical qualities. The main areas of application are in particle measurement technology, medicine, biochemistry and microelectronics etc.	microparticles.de
Minerva Biolabs GmbH	Minerva Biolabs develops and produces IVD kits for diagnosing pathogens and for contamination control, especially mycoplasma in cell cultures and biopharmaceutical products. Minerva Biolabs is also active in ensuring water quality with sensitive processes for detecting legionella. Our distributors ensure that our products are available worldwide, quickly and at a good price.	minerva-biolabs.com
mivenion GmbH	mivenion is a life-science company founded in Berlin aiming on the development and commercialization of diagnostic and therapeutic products. The company is built on two innovative technologies: the fluorescence camera system Xiralite for diagnostic imaging of early rheumatoid arthritis and a proprietary bioactive polymer drug development platform. Xiralite is mivenion's first product on the market.	mivenion.com
MLB Mikrobiologisches Labor GmbH	Accredited test laboratory for drinking water, clean rooms, sterility, bioburdens. D-PL-13398-01-00, EN 17025. Accreditation according to VDI 6022	mikroberlin.de
molConcept GmbH	We offer computational drug design, rational drug design, and efficient simulation algorithms for molecular systems	molconcept.com
Molnar-Institut für angewandte Chromatographie	Molnar-Institute, established in 1981, offers you a complete scientific and technical service for all problems concerning Quality by Design (QbD) for HPLC-methods. We develop for you the Design Space for your HPLC-separation and establish Critical Quality Attributes (CQA's). We offer detailed DryLab-courses and show you, how to develop robust methods in the Design Space and how to save time. We supply and implement the DryLab-software and train your coworkers. We assist you in automated method development processes and support you in the selection of proper instruments, their installation and use.	molnar-institute.com
MOLOGEN AG	MOLOGEN AG is a biopharmaceutical company based in Berlin and specializes in the development of novel DNA-based medicines against cancer and vaccines against infectious diseases. The proprietary platform technologies MIDGE® and dSLIM® build the foundation for all business activities. The company was founded 1998 and was one of the first biotechnology companies to go public.	mologen.com
MolTech Molekular Technology GmbH	Custom research and process development in the area of bioluminescence, production of restrictase and photo proteins	mt-berlin.com
Nano Access Technologies Limited	The company addresses the combined access to key technologies such as life science and nanotechnology. As a first product, a low cost AFM for operation with so-called active cantilevers has been developed. Besides this, functionalized cantilevers for future biosensors are another focus of the company.	nano-access.com
Nanalytics Gesellschaft für Kolloidanalytik mbH	We are a contract laboratory specializing in the physico-chemical characterization of pharmaceutical proteins, biopolymers, nanoparticles and colloidal systems. Our core-competences are Analytical Ultracentrifugation, in combination with Static and Dynamic Light Scattering as well as spectroscopic (CD, fluorescence) and thermodynamic techniques (ITC, DSC).	nanalytics.de
Nanopartica GmbH	Nanopartica GmbH optimizes existing products of other companies, but are also developing new products and materials. In particular, companies in surface-, bio-, and medical-technology can benefit from nanopartica. By means of functionalized polymers, we can encapsulate guest molecules (drugs, dyes, vitamins), particles (gold, silver, platinum), or ions. This will indirectly change the guests' properties and expands its scope.	nanopartica.com
NanoPET Pharma GmbH	As a technology and service provider to the biopharmaceutical industry nanoPET focuses on the R&D, production as well as marketing of innovative drug substances for diagnostic imaging based on novel nanoparticulate materials. nanoPET offers consulting and contract research services, preclinical contrast agents (MRT, CT, US, NIR, PET) as catalog items and pursues the preclinical development of its patented core technology of inorganic nanoparticle PET tracers.	nanopet-pharma.com
NovaBiotec® Dr. Fechter GmbH	Microbiological and chemical investigations, in particular of soil, water and air samples, planning / inspection of sanitation, in particular analytics and sanitation support for mould and dry rot, incl. education in this field. Delivery of production auxiliaries and support for biogas plants with biological treatment processes incl. application, insulation and preservation of enzymes. Research, development and marketing of test kits for breweries and malthouses.	novabiotec.de

Biotech Companies		
Novamol GmbH	Development and manufacture of human and veterinary food supplements and health-enhancing products	novamol.com
NOXXON Pharma AG	NOXXON Pharma is a biotechnology company developing a promising new class of therapeutics called Spiegelmers, which are oligonucleotides made from the L-stereoisomer of RNA. Spiegelmers can be engineered to bind specifically to a precisely defined biological target and have been shown to be potent inhibitors. Clinical and pre-clinical studies of Spiegelmers to date have shown them to be exceptionally safe, well-tolerated, biologically stable and non-immunogenic. NOXXON has three programs in development, two of which have successfully completed their first Phase I clinical studies. The company has approximately 60 employees based at its headquarter in Berlin, Germany.	noxxon.com
NutriNeu GmbH	NutriNeu GmbH develops a new generation of pre and probiotics. First products are based on microorganisms that were isolated with our proprietary GlycoScreen technology (antibody directed isolation of microorganisms expressing specific carbohydrate structures). Besides developing own products, NutriNeu GmbH offers services in the fields of microbiology, process development and Glycoanalytic. NutriNeu GmbH also helps customers to investigate the probiotic properties of their microorganisms.	
OpTricon Entwicklungsgesellschaft f. optische Technologien	OpTricon develops and produces mobile readers for quantitative analyzes of Immunoassays for Point-of-Care-diagnostics, especially Lateral Flow Assays (LFA). Additional business segments are components and Systems for signal transmission and sensors for Ibioanalytics. opTricon develops the devices in partnership with the customers and works as OEM-suppliers and is certified by TÜV Rheinland according EN ISO 13485:2003+AC: 2007 and EN ISO 9001:2008.	optricon.de
ORGANOBALANCE GmbH	ORGANOBALANCE is a company specializing in microbial strain development and screening. As a R&D contractor ORGANOBALANCE develops new biological products in the areas of nutrition, personal care and health care. The company draws on its own collection of microbial strains suitable for food applications and its OASSYS® bioassay systems. In the field of metabolic engineering? ORGANOBALANCE exploits Saccharomyces cerevisiae yeast for synthesis of substances for the industrial and pharmaceutical industry.	organobalance.com
ORGANOBALANCE Medical AG	ORGANOBALANCE Medical AG funds and promotes the research and development of novel therapies based on specific probiotic cultures, aiming to develop active substances and mechanisms for innovative medicinal products and medical devices, as well as offer new therapeutic concepts for hitherto inadequately treatable indications.	organobalancemedical.com
ovalehn GmbH	Production and application of specific recipes –containing IgY for diagnostics and oral, passive immune therapy	ovalehn.de
Pentracor GmbH	In the case of cardiac infarction, C-reactive protein (CRP) results in an increase of the primary damage. Based on a new prototype, the company Pentracor GmbH aims to develop an adsorber for therapeutic reduction of CRP, lead it to approval, establish its certified production and market the product after clinical validation.	pentracor.com
Peptides&elephants GmbH	Custom synthesis of peptides and peptide libraries. Development parallel Synthesis technologies. Distributor of Peptide Synthesis Automation.	peptides.de
PharmaSol GmbH	Modification of ingredients or introduction of new metabolic pathways in plants with gene-technology methods	pharmasol-berlin.de
PlasmaChem GmbH	PlasmaChem GmbH is an innovative R&D and manufacturing company specializing in nanomaterials, plasma- and ultra-thin film technologies. The company manufactures nano-coated medical implants (stents), nanomaterials, additives for metal plating (applied e. g. by Siemens AG), new additives to engine oils on the base of nanodiamonds and other industrial nanoproductions.	plasmachem.com
PolyAn, Gesellschaft zur Herstellung von Polymeren für spezielle Anwendungen und Analytik mbH	PolyAn is specialised in Molecular Surface Engineering (MSE) and Surface Molecular Imprinting (SMI). PolyAn's proprietary MSE-technology platform is used for the production of microarray slides, e. g. for oligo-, peptide or protein arrays. For multiplex-bead arrays PolyAn has developed a range of functionalised, fluorescence encoded PMMA microparticles.	poly-an.de
Preclinics Gesellschaft für präklinische Forschung mbH	Preclinics is a commercial cooperation partner for preclinical research and development. As a competent, creative and experienced partner preclinics investigates pharmaceutical substances, therapeutic methods and proceedings as well as medical products during the preclinical phase. Additional we provide custom antibody production in llama, goat, sheep, rabbit and other species.	preclinics.com
ProBioGen AG	ProBioGen is a specialist in mammalian cell development, process engineering and GMP manufacturing of biopharmaceutical drug substances. Offering state-of-the-art contract development and manufacturing services as well as access to proprietary cell lines (AGE1, cell lines(R)) for the manufacturing of biopharmaceuticals and vaccines. The company possesses the manufacturing authorisation from the competent authority and meets the quality standards required by the EMEA and the FDA guidelines.	probiogen.de
Protealmmun GmbH	Protealmmun produces a unique range of recombinant proteases for medical and pharmaceutical research. Our proteins are designed for structural and functional studies of proteases screening and evaluation of protease inhibitors and modulators. Furthermore, we develop highly sensitive ELISA Kits and antibodies.	protealmmun.de

Biotech Companies		
PROTEKUM – Umweltinstitut GmbH, Oranienburg	We plan to eliminated fluid und solid waste products in a manner which is compatible with environment protection. Our methodology is largely based on painstaking analysis. We use modern equipment and scientific methods. Protekum offers high-quality products and services in environmental analysis redevelopment.	protekum.de
Proteome Factory AG	Biomarker & target discovery, validation, analysis of food and ingredients, absolute quantification of proteins and peptides, sequencing and characterization of proteins and antibodies (CDR), 2DE and LC-MS based proteomics studies, pharmacokinetics, pharmaco, immuno and membrane proteomics, protein identification, characterization of proteins and peptides (PTMs, e. g. phosphorylation, glycosilation), quality control, mass determination, N-terminal amino acid sequencing, silver staining kit etc.	proteomefactory.com
Provitro GmbH	Provitro combines more than ten years of experiences in commercialisation of cell culture technologies, Tissue Microarrays and immunohistochemical analyses with the scientific expertise of the Pathological Institute of the Charité, Berlin. Based on a quality management system according to ISO 9001:2008, we provide our customers not only with high-quality products, CE marked in-vitro diagnostics and state-of-the-art services but also with individual solutions for their specific requests.	provitro.de
Rapidozym Gesellschaft für Laborhandel und DNA Diagnostika mbH	Expertise of cell biologists cell manufacturing and clean room technology specialists. Focuses on clinical stem cell product development portfolio are stroke, myocardial infarction and plastic surgery.	
RENE SA UG (haftungsbeschränkt)	Manufacturing and distribution of rapid tests, mainly for medical purposes (Point of Care Testing).	renesa.de
Revotar Biopharmaceuticals AG	Revotar develops innovative small molecule drugs (SMD) for the treatment of chronic inflammatory disorders such as, chronic obstructive pulmonary disease (COPD), Acute Lung Injury (ALI/ARDS) and ischemia/reperfusion. With its drug candidate bimosiamose, Revotar has the worldwide most advanced pan-selectin-antagonist in clinical development in its product pipeline.	revotar.de
RiNA GmbH	RiNA has developed systems for cell-free protein biosynthesis based on pro- and eukaryotic cell lysates. A synthesis service is realised in RiNA's own laboratories and complements the EasyXpress Kits (Qiagen). The purchase of Roche's RTS-products enables RiNA now to be a key player in the field of cellfree biosynthesis with a large variety of products. Another research focus is the development of aptamers (DNA and RNA) for biosensors.	rina-gmbh.eu
RIPAC-LABOR GmbH	RIPAC-LABOR offers high-quality diagnoses of bacterial infections, particularly in poultry, pigs and cattle, but also in other farm and domestic animals. The company uses pathogen differentiation to provide quick and effective methods for fighting pathogens. It performs resistance tests and epidemiological analyses and also focuses on producing herd-specific vaccines.	ripac-labor.de
RNAX GmbH	RNAX specializes in RNA-Interference services. It offers functional validations of si- and shRNAs, target validation studies using automated high throughput approaches, as well as whole genome screens with automated assays.	RNAX.de
RNL Europe GmbH	Manufacturing of stem cells from bone marrow and adipose tissue for therapeutic and plastic-aesthetical application. Manufacturing of adult stem cells for research (mesenchymal stem cells, endothelial precursor cells). Banking of stem cells.	pharmacell.eu
Roboklon GmbH	Distribution, Marketing and Development of Products for Molecular Biological Research and Genetic Engineering.	roboklon.de
ROVALAB GmbH	Our Master Mixes for QPCR, Standard-, Hot Start- and High Fidelity PCR as well as our high quality critical raw materials and reagents such as DNA Polymerases and dNTPs are designed to help you successfully and rapidly solve your scientific and manufacturing tasks.	rovalab.com
Royal Biotech GmbH	Royal focuses on developing, manufacturing and marketing innovative kits, portable or micro-structured systems, and the next generation of diagnostic chips for near real-time environmental, food safety, disease and laboratory diagnostics	royalbiotech.de
Scienion AG	Scienion is a life science company in the markets of dispensing systems and microarray technologies. The product portfolio comprises hardware, consumables and services. Scienion's leading product is the sciFLEXARRAYER dispensing system, available in a product line of six size versions. The dispenser allows the aspiration of ultra low liquid volumes from different reservoirs and non-contact micro drop delivery in the picoliter to microliter range onto a variety of carriers.	scienion.de
Sepiatec GmbH	Production, development and sales of automated HPLC machines for high-throughput purification and fractioning of complex substance compounds	sepiatec.com
Seramun Diagnostica GmbH	Seramun offers peptide synthesis, purification and conjugation of proteins, production of antibodies, customer research, In-vitro Diagnostics. We focus on the development and production of enzyme immunoassays for diagnosis of viral and bacterial infections and autoimmune diseases of the gastrointestinal tract, the development of multi-parameter assays as microtitre plate assays and as membrane immunoassays, as well as development of ready-to-use substrate solutions and for protein stabilizers.	seramun.com

Biotech Companies		
SGS INSTITUT FRESENIUS Berlin GmbH & Co. KG	Analytical laboratory services and consulting for development, production and quality control of drugs	institut-fresenius.de
SIFIN Institut für Immunpräparate und Nährmedien GmbH Berlin	Development, production and purification of monoclonal antibodies for use in diagnostics. Development and production of blood grouping reagents, Serafol® bedside cards and test reagents for serotyping of Salmonellae, Shigellae, E. coli and Yersinia. Development and production of culture media for microbiological diagnosis.	sifin.de
Signature Diagnostics AG	Signature Diagnostics is dedicated to the discovery, validation and commercial development of novel diagnostic products that predict outcome and drug response in patients with colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and ovarian cancer. Signature believes that patient selection and stratification based on molecular gene signatures will soon become an important component of routine cancer treatment.	signature-diagnostics.de
Silence Therapeutics AG	SILENCE Therapeutics AG, Berlin, is a leading RNAi therapeutics company with strong patents issued in the US and Europe. SILENCE has developed novel, proprietary short interfering RNA (siRNA) molecules and proprietary systemic delivery systems for siRNA. SILENCE has validating partnerships with AstraZeneca (\$400m), Pfizer (\$95m), Quark/Novartis (\$80m) and Dainippon Sumitomo (n.d.). There are 5 clinical AtuRNAi-programs of which 4 are driven by its partners Pfizer & Quark/Novartis. SILENCE is listed through its holding company Silence Therapeutics plc, London, at the AIM.	silence-therapeutics.com
SLM- Speziallabor für angewandte Mikrobiologie GmbH	Microbiological quality control for medical devices, pharmaceuticals, cosmetics, drinking water, foodstuff, monitoring in clean rooms.	slm-fiedler.de
STRATEC Molecular GmbH	STRATEC Molecular GmbH is a globally active provider of innovative system solutions for nucleic acid sample collection, stabilization, and both manual and automated purification from any sample type. Since 1992 the company is internationally respected for its outstanding and high performance technology platforms and offers a broad spectrum of superior products for molecular diagnostics, drug discovery and Life Science research.	invitek.de
Strix Diagnostics GmbH	Strix Diagnostics is a medical diagnostics company specializing in customized development of certified analytical systems for multiparameter in-vitro diagnostics.	strix-diagnostics.de
Surflay Nanotec GmbH	Surflay Nanotec GmbH, a spin-off company from Capsulation NanoScience AG, is specialized on coating colloidal and planar materials with functional films. Key technology is the patented LbL-Technology® with polymers. Applications are in the fields of separation materials, pigment encapsulation, bio-sensing and diagnostic particles. In addition to customer tailored projects Surflay offers an unique range of products of tunable multifunctional nano- or microparticles and dye-labeled polymers.	surflay.com
Thanares GmbH	Development, use and marketing of analytical process for diagnostic and therapeutic purposes. Future business activities: detection process for bioactive substances in bodily fluids, isolation, characterization and investigation of bioactive compounds from plants, in particular insoluble proteins or low concentrations of proteins, development of low cost genetic systems for over-expression and/or production of such proteins.	thanares.com
TheraKine BioDelivery GmbH	Development of antibody drug delivery systems and related tasks	therakine.com
TIB MOLBIOL Syntheselabor GmbH	In 1990, TIB MOLBIOL became the first German manufacturer of oligonucleotides. In addition to designing and synthesizing primers and probes for Real-Time PCR assays, we develop and produce LightMix® Kits for Roche Diagnostics LightCycler® Instruments, covering applications in Clinical Chemistry, Pharmacogenetics, Pathogen Detection, as well as Cancer Research. TIB MOLBIOL is ISO 13485 and ISO 9001 certified.	tib-molbiol.com
TransTissue Technologies GmbH	TransTissue has been a subsidiary of BioTissue Technologies, Freiburg since September 2001. With more than 15 years of experience in regenerative medicine, the scientists of TransTissue Technologies have developed second-generation autologous tissue replacements, e.g. cartilage and bone grafts. We are mainly concerned with inventions and the development of tissue engineering products for regenerative medicine. We offer a broad panel of services in the field of regenerative medicine.	transtissue.com
UGA Biopharma	UGA Biopharma a private Research and Development company, focuses on Research, Development and Commercialization of Biopharmaceutical products under contract with other Biopharmaceutical companies. UGA Biopharma conducts power of biosciences to develop high-tech, last generation of biomedicine, diagnostic kits, molecular biology items and also offers world class services in biotechnology area.	ugabiopharma.com
Umwelttechnik Dr. Bartetzko GmbH	Feasibility studies, development, planning, construction and operation of biotechnological plants for groundwater, process water and waste water purification. Accredited microbiological laboratory for the investigation of drinking water, groundwater, bath water, soils, food, anti-microbial active ingredients and sterility according to Ph.Eur, approved in accordance with BiostoffV and the German infection protection act (Infektionsschutzgesetz).	bartetzko.com
VasoTissue Technologies GmbH	The company is active in the field of product development for advanced medical therapies. For its first product - the endothelialised vascular graft ("VasoGraft")- VasoTissue obtained a manufacturing license in 2008. Currently, VasoTissue's focus is on conducting its first clinical trial.	vasotissue.de

Biotech Companies		
WITA GmbH	WITA is a high technology service and product company specialized for protein and proteome analysis using high resolution NEPHGE 2-DE (up to 410 mm x 300 mm gel size, up to 10.000 individual protein spots) and mass spectrometry. HPLC, Edman N-terminal sequencing, synthesis of "tricky" unusual peptides	wita.de
Zellwerk GmbH	Zellwerk produces the proprietary Z [®] RP cell cultivation system, comprising rotating bed bioreactor, GMP Breeder, Control Unit, software. Bioreactors with 50-5000 ml volume, 0,2-2 m ² seeding surface, different cell carriers, can be delivered. In this culturing system cells grow tissue-like, being embedded in self-generated extra-cellular matrix. The technology opens unique opportunities for the GMP-compliant expansion of stem cells and primary cells, manufacturing of cell-seeded implants as well as production of recombinant proteins.	zellwerk.biz
Zentrum für molekulare Onkologie GmbH	Innovative methods for diagnostic and therapy of tumor diseases - Molecular genetics (K-RAS, PCA3, Septin9, ...) - Chemoresistance assay for prediction of chemotherapy - Pathology Development of new biomarkers and analytical services for studies	molekulare-onkologie.eu
Zytomed Systems GmbH	Zytomed Systems' focus is the development, production and distribution of antibodies and detection systems for immunohistochemical cancer diagnostics as well as reagents and kits for in-situ hybridisation.	zytomed-systems.de



Promotion and Financing for Bio-Tech Firms

Are you a technology-based firm in the bio-tech branch, and are you planning to invest in the State of Brandenburg? We can support your project with grants, loans at reduced interest rates and risk and equity capital. Just contact us!

InvestitionsBank des Landes Brandenburg

Phone: +49 331 660-1256 · E-mail: technologie@ilb.de · www.ilb.de

ILB InvestitionsBank
des Landes
Brandenburg

BERLIN-CHEMIE is a pharmaceutical company with a long tradition, based in Berlin ...



Research is carried out here

Our research focuses on: analytical chemistry, pharmaceutical development and clinical research. Our findings lead to innovative and proven quality compounds. In this way, we improve quality of life for many people.

Here we produce ...

The main focus of our product portfolio is medication for pain and diabetes therapy as well as for the treatment of disease relating to the cardiac and circulatory system or the thyroid gland. Patients have placed their trust in our medicines for over 100 years.

From here we apply our know how on the market ...

Especially in the eastern European markets; there we have over 31 representative offices. We supply patients worldwide within the Italian Menarini Group network.

BERLIN-CHEMIE, a company in the Menarini Group, stands for tradition and innovation from Berlin.



BERLIN-CHEMIE
MENARINI

- For further information:

BERLIN-CHEMIE AG · Glienicke Weg 125 · 12489 Berlin
telephone: (030) 67 07-0 · internet: www.berlin-chemie.de



berlin Berlin

**Life Sciences.
Living Research.
Berlin. Brandenburg.**



A vibrant network

Berlin-Brandenburg is one of Europe's leading locations for the Life Sciences. It is also an R&D capital that magnetically attracts the world's top scientists. Here you'll find attractive subsidy conditions, close linkages between business and science, the highest concentration of R&D in Europe, a dynamic startup scene and a multifaceted entrepreneurial environment made up of roughly 480 pharmaceutical, biotech and medical engineering companies. Come discover this one-of-a-kind landscape for scientists and entrepreneurs.

www.biotop.de/business



**Ready for take off 2012:
Airport Berlin Brandenburg International**

**THE GERMAN CAPITAL REGION
MORE VALUE FOR YOUR INVESTMENT**